



REC'D 03 DEC 2004

WIPO

PCT

Kongeriget Danmark

Patent application No.: PA 2003 01367

Date of filing: 19 September 2003

Applicant:
(Name and address) Novo Nordisk A/S
Novo Allé
DK-2880 Bagsværd
Denmark

Title: Nye forbindelser

IPC:

This is to certify that the attached documents are exact copies of the above mentioned patent application as originally filed.

PRIORITY DOCUMENT
SUBMITTED OR TRANSMITTED IN
COMPLIANCE WITH
RULE 17.1(a) OR (b)



Patent- og Varemærkestyrelsen
Økonomi- og Erhvervsministeriet

15 November 2004

Pia Høybye-Olsen
Pia Høybye-Olsen

BEST AVAILABLE COPY

19 SEP. 2003

1

Novel GLP-1 derivatives

Modtaget

FIELD OF THE INVENTION

The present invention relates to novel derivatives of glucagon-like-peptide-1 (GLP-1) and fragments thereof and analogues of such fragments which have a protracted profile of action and methods of making and using them. The invention furthermore relates to novel derivatives of exendin and the use of such derivatives.

10 BACKGROUND OF THE INVENTION

Peptides are widely used in medical practice, and since they can be produced by recombinant DNA technology it can be expected that their importance will increase also in the years to come. When native peptides or analogues thereof are used in therapy it is generally found that they have a high clearance. A high clearance of a therapeutic agent is inconvenient in cases where it is desired to maintain a high blood level thereof over a prolonged period of time since repeated administrations will then be necessary. Examples of peptides which have a high clearance are: ACTH, corticotropin-releasing factor, angiotensin, calcitonin, insulin, glucagon, glucagon-like peptide-1, glucagon-like peptide-2, insulin-like growth factor-1, insulin-like growth factor-2, gastric inhibitory peptide, growth hormone-releasing factor, pituitary adenylate cyclase activating peptide, secretin, enterogastrin, somatostatin, somatotropin, somatomedin, parathyroid hormone, thrombopoietin, erythropoietin, hypothalamic releasing factors, prolactin, thyroid stimulating hormones, endorphins, enkephalins, vasopressin, oxytocin, opioids and analogues thereof, superoxide dismutase, interferon, asparaginase, arginase, arginine deaminase, adenosine deaminase and ribonuclease. In some cases it is possible to influence the release profile of peptides by applying suitable pharmaceutical compositions, but this approach has various shortcomings and is not generally applicable.

The hormones regulating insulin secretion belong to the so-called enteroinsular axis, designating a group of hormones, released from the gastrointestinal mucosa in response to the presence and absorption of nutrients in the gut, which promote an early and potentiated release of insulin. The enhancing effect on insulin secretion, the so-called incretin effect, is probably essential for a normal glucose tolerance. Many of the gastrointestinal hormones, including gastrin and secretin (cholecystokinin is not insulinotropic in man), are insulinotropic, but the only physiologically important ones, those that are responsible for the incretin

effect, are the glucose-dependent insulintropic polypeptide, GIP, and glucagon-like peptide-1 (GLP-1). Because of its insulintropic effect, GIP, isolated in 1973 (1) immediately attracted considerable interest among diabetologists. However, numerous investigations carried out during the following years clearly indicated that a defective secretion of GIP was not involved in the pathogenesis of insulin dependent diabetes mellitus (IDDM) or non insulin-dependent diabetes mellitus (NIDDM) (2). Furthermore, as an insulintropic hormone, GIP was found to be almost ineffective in NIDDM (2). The other incretin hormone, GLP-1 is the most potent insulintropic substance known (3). Unlike GIP, it is surprisingly effective in stimulating insulin secretion in NIDDM patients. In addition, and in contrast to the other insulintropic hormones (perhaps with the exception of secretin) it also potently inhibits glucagon secretion. Because of these actions it has pronounced blood glucose lowering effects particularly in patients with NIDDM.

GLP-1, a product of the proglucagon (4), is one of the youngest members of the secretin-VIP family of peptides, but is already established as an important gut hormone with regulatory function in glucose metabolism and gastrointestinal secretion and metabolism (5). The glucagon gene is processed differently in the pancreas and in the intestine. In the pancreas (9), the processing leads to the formation and parallel secretion of 1) glucagon itself, occupying positions 33-61 of proglucagon (PG); 2) an N-terminal peptide of 30 amino acids (PG (1-30)) often called glicentin-related pancreatic peptide, GRPP (10, 11); 3) a hexapeptide corresponding to PG (64-69); 4) and, finally, the so-called major proglucagon fragment (PG (72-158)), in which the two glucagon-like sequences are buried (9). Glucagon seems to be the only biologically active product. In contrast, in the intestinal mucosa, it is glucagon that is buried in a larger molecule, while the two glucagon-like peptides are formed separately (8). The following products are formed and secreted in parallel: 1) glicentin, corresponding to PG (1-69), with the glucagon sequence occupying residues Nos. 33-61 (12); 2) GLP-1(7-36)amide (PG (78-107))amide (13), not as originally believed PG (72-107)amide or 108, which is inactive). Small amounts of C-terminally glycine-extended but equally bioactive GLP-1(7-37), (PG (78-108)) are also formed (14); 3) intervening peptide-2 (PG (111-122)amide) (15); and 4) GLP-2 (PG (126-158)) (15, 16). A fraction of glicentin is cleaved further into GRPP (PG (1-30)) and oxyntomodulin (PG (33-69)) (17, 18). Of these peptides, GLP-1, has the most conspicuous biological activities.

Being secreted in parallel with glicentin/enteroglucagon, it follows that the many studies of enteroglucagon secretion (6, 7) to some extent also apply to GLP-1 secretion, but GLP-1 is metabolised more quickly with a plasma half-life in humans of 2 min (19). Carbohydrate or fat-rich meals stimulate secretion (20), presumably as a result of direct interaction of yet un-

absorbed nutrients with the microvilli of the open-type L-cells of the gut mucosa. Endocrine or neural mechanisms promoting GLP-1 secretion may exist but have not yet been demonstrated in humans.

5 The incretin function of GLP-1(29-31) has been clearly illustrated in experiments with the GLP-1 receptor antagonist, exendin 9-39, which dramatically reduces the incretin effect elicited by oral glucose in rats (21, 22). The hormone interacts directly with the β -cells via the GLP-1 receptor (23) which belongs to the glucagon/VIP/calcitonin family of G-protein-coupled 7-transmembrane spanning receptors. The importance of the GLP-1 receptor in
10 regulating insulin secretion was illustrated in recent experiments in which a targeted disruption of the GLP-1 receptor gene was carried out in mice. Animals homozygous for the disruption had greatly deteriorated glucose tolerance and fasting hyperglycaemia, and even heterozygous animals were glucose intolerant (24). The signal transduction mechanism (25) primarily involves activation of adenylate cyclase, but elevations of intracellular Ca^{2+} are
15 also essential (25, 26). The action of the hormone is best described as a potentiation of glucose stimulated insulin release (25), but the mechanism that couples glucose and GLP-1 stimulation is not known. It may involve a calcium-induced calcium release (26, 27). As already mentioned, the insulinotropic action of GLP-1 is preserved in diabetic β -cells. The relation of the latter to its ability to convey "glucose competence" to isolated insulin-secreting
20 cells (26, 28), which respond poorly to glucose or GLP-1 alone, but fully to a combination of the two, is also not known. Equally importantly, however, the hormone also potently inhibits glucagon secretion (29). The mechanism is not known, but seems to be paracrine, via neighbouring insulin or somatostatin cells (25). Also the glucagonostatic action is glucose-dependent, so that the inhibitory effect decreases as blood glucose decreases. Because of
25 this dual effect, if the plasma GLP-1 concentrations increase either by increased secretion or by exogenous infusion the molar ratio of insulin to glucagon in the blood that reaches the liver via the portal circulation is greatly increased, whereby hepatic glucose production decreases (30). As a result blood glucose concentrations decrease. Because of the glucose dependency of the insulinotropic and glucagonostatic actions, the glucose lowering effect is self-limiting, and the hormone, therefore, does not cause hypoglycaemia regardless of dose
30 (31). The effects are preserved in patients with diabetes mellitus (32), in whom infusions of slightly supraphysiological doses of GLP-1 may completely normalise blood glucose values in spite of poor metabolic control and secondary failure to sulphonylurea (33). The importance of the glucagonostatic effect is illustrated by the finding that GLP-1 also lowers blood
35 glucose in type-1 diabetic patients without residual β -cell secretory capacity (34).

In addition to its effects on the pancreatic islets, GLP-1 has powerful actions on the gastrointestinal tract. Infused in physiological amounts, GLP-1 potently inhibits pentagastrin-induced as well as meal-induced gastric acid secretion (35, 36). It also inhibits gastric emptying rate and pancreatic enzyme secretion (36). Similar inhibitory effects on gastric and pancreatic secretion and motility may be elicited in humans upon perfusion of the ileum with carbohydrate- or lipid-containing solutions (37, 38). Concomitantly, GLP-1 secretion is greatly stimulated, and it has been speculated that GLP-1 may be at least partly responsible for this so-called "ileal-brake" effect (38). In fact, recent studies suggest that, physiologically, the ileal-brake effects of GLP-1 may be more important than its effects on the pancreatic islets. Thus, in dose response studies GLP-1 influences gastric emptying rate at infusion rates at least as low as those required to influence islet secretion (39).

GLP-1 seems to have an effect on food intake. Intraventricular administration of GLP-1 profoundly inhibits food intake in rats (40, 42). This effect seems to be highly specific. Thus, N-terminally extended GLP-1 (PG 72-107)amide is inactive and appropriate doses of the GLP-1 antagonist, exendin 9-39, abolish the effects of GLP-1 (41). Acute, peripheral administration of GLP-1 does not inhibit food intake acutely in rats (41, 42). However, it remains possible that GLP-1 secreted from the intestinal L-cells may also act as a satiety signal.

Not only the insulinotropic effects but also the effects of GLP-1 on the gastrointestinal tract are preserved in diabetic patients (43), and may help curtailing meal-induced glucose excursions, but, more importantly, may also influence food intake. Administered intravenously, continuously for one week, GLP-1 at 4 ng/kg/min has been demonstrated to dramatically improve glycaemic control in NIDDM patients without significant side effects (44). The peptide is fully active after subcutaneous administration (45), but is rapidly degraded mainly due to degradation by dipeptidyl peptidase IV-like enzymes (46, 47).

The amino acid sequence of GLP-1 is given *i.a.* by Schmidt *et al.* (*Diabetologia* 28 704-707 (1985)). Although the interesting pharmacological properties of GLP-1(7-37) and analogues thereof have attracted much attention in recent years only little is known about the structure of these molecules. The secondary structure of GLP-1 in micelles has been described by Thorton *et al.* (*Biochemistry* 33 3532-3539 (1994)), but in normal solution, GLP-1 is considered a very flexible molecule. Surprisingly, we found that derivatisation of this relatively small and very flexible molecule resulted in compounds whose plasma profile were highly protracted and still had retained activity.

GLP-1 and analogues of GLP-1 and fragments thereof are potentially useful *i.a.* in the treatment of type 1 and type 2 diabetes. However, the high clearance limits the usefulness of these compounds, and thus there still is a need for improvements in this field. Accordingly, it is one object of the present invention to provide derivatives of GLP-1 and analogues thereof which have a protracted profile of action relative to GLP-1(7-37). It is a further object of the invention to provide derivatives of GLP-1 and analogues thereof which have a lower clearance than GLP-1(7-37). It is a further object of the invention to provide a pharmaceutical composition comprising a compound according to the invention and to use a compound of the invention to provide such a composition. Also, it is an object of the present invention to provide a method of treating insulin dependent and non-insulin dependent diabetes mellitus.

The number of known endogenous peptides and proteins with interesting biological activities is growing rapidly, also as a result of the ongoing exploration of the human genome. Due to their biological activities, many of these peptides and proteins could in principle be used as therapeutic agents. Endogenous peptides are, however, not always suitable as drug candidates because these peptides often have half-lives of few minutes due to rapid degradation by peptidases and/or due to renal filtration and excretion in the urine. It has been shown (Zobel et al., *Bioorg. Med. Chem. Lett.* 2003, 13, 1513-1515) that the plasma half-life of a given peptide may be significantly enhanced by reversible attachment of this peptide to plasma proteins, such as albumin or gamma-globulin. Human serum albumin (HSA) has, for instance, a half-life of more than one week. This reversible attachment requires a compound (= albumin binding residue) which can be linked to the therapeutic agent, and which has a high binding affinity to albumin while bound to said therapeutic agent. Using the known strategies for reversible binding of endogenous proteins such as GLP-1 to albumin it is however often observed that the albumin binding fraction of the therapeutic agent has diminished or no activity on the GLP-1 receptor. One aspect of this invention is to introduce a hydrophilic linker between the therapeutic protein and the albumin binding residue in such a manner that the free fraction as well as the albumin binding fraction of the therapeutic protein are both active on the target which may be a GPCR receptor such as the GLP-1 receptor or an enzyme.

References.

1. Pederson RA. Gastric Inhibitory Polypeptide. In Walsh JH, Dockray GJ (eds) Gut peptides: Biochemistry and Physiology. Raven Press, New York 1994, pp. 217-259.
2. Krarup T. Immunoreactive gastric inhibitory polypeptide. *Endocr Rev* 1988;9:122-134.
- 5 3. Ørskov C. Glucagon-like peptide-1, a new hormone of the enteroinsular axis. *Diabetologia* 1992; 35:701-711.
4. Bell GI, Sanchez-Pescador R, Laybourn PJ, Najarian RC. Exon duplication and divergence in the human proglucagon gene. *Nature* 1983; 304: 368-371.
- 10 5. Holst JJ. Glucagon-like peptide-1 (GLP-1) - a newly discovered GI hormone. *Gastroenterology* 1994; 107: 1848-1855.
6. Holst JJ. Gut glucagon, enteroglucagon, gut GLI, glicentin - current status. *Gastroenterology* 1983;84:1602-1613.
- 15 7. Holst JJ, Ørskov C. Glucagon and other proglucagon-derived peptides. In Walsh JH, Dockray GJ, eds. Gut peptides: Biochemistry and Physiology. Raven Press, New York, pp. 305-340, 1993.
- 20 8. Ørskov C, Holst JJ, Knuhtsen S, Baldissera FGA, Poulsen SS, Nielsen OV. Glucagon-like peptides GLP-1 and GLP-2, predicted products of the glucagon gene, are secreted separately from the pig small intestine, but not pancreas. *Endocrinology* 1986;119:1467-1475.
- 25 9. Holst JJ, Bersani M, Johnsen AH, Kofod H, Hartmann B, Ørskov C. Proglucagon processing in porcine and human pancreas. *J Biol Chem*, 1994; 269: 18827-1883.
10. Moody AJ, Holst JJ, Thim L, Jensen SL. Relationship of glicentin to proglucagon and glucagon in the porcine pancreas. *Nature* 1981; 289: 514-516.
- 30 11. Thim L, Moody AJ, Purification and chemical characterisation of a glicentin-related pancreatic peptide (proglucagon fragment) from porcine pancreas. *Biochim Biophys Acta* 1982;703:134-141.

12. Thim L, Moody AJ. The primary structure of glicentin (proglucagon). *Regul Pept* 1981;2:139-151.
13. Ørskov C, Bersani M, Johnsen AH, Højrup P, Holst JJ. Complete sequences of glucagon-like peptide-1 (GLP-1) from human and pig small intestine. *J. Biol. Chem.* 1989;264:12826-12829.
14. Ørskov C, Rabenhøj L, Kofod H, Wettergren A, Holst JJ. Production and secretion of amidated and glycine-extended glucagon-like peptide-1 (GLP-1) in man. *Diabetes* 1991; 43: 535-539.
15. 15. Buhl T, Thim L, Kofod H, Ørskov C, Harling H, & Holst JJ: Naturally occurring products of proglucagon 111-160 in the porcine and human small intestine. *J. Biol. Chem.* 1988;263:8621-8624.
16. Ørskov C, Buhl T, Rabenhøj L, Kofod H, Holst JJ: Carboxypeptidase-B-like processing of the C-terminus of glucagon-like peptide-2 in pig and human small intestine. *FEBS letters*, 1989;247:193-106.
17. Holst JJ. Evidence that enteroglucagon (II) is identical with the C-terminal sequence (residues 33-69) of glicentin. *Biochem J.* 1980;187:337-343.
18. Bataille D, Tatemoto K, Gespach C, Jörmvall H, Rosselin G, Mutt V. Isolation of glucagon-37 (bioactive enteroglucagon/oxyntomodulin) from porcine jejunum-ileum. Characterisation of the peptide. *FEBS Lett* 1982;146:79-86.
19. Ørskov C, Wettergren A, Holst JJ. The metabolic rate and the biological effects of GLP-1 7-36amide and GLP-1 7-37 in healthy volunteers are identical. *Diabetes* 1993;42:658-661.
20. Elliott RM, Morgan LM, Tredger JA, Deacon S, Wright J, Marks V. Glucagon-like peptide-1 (7-36)amide and glucose-dependent insulinotropic polypeptide secretion in response to nutrient ingestion in man: acute post-prandial and 24-h secretion patterns. *J Endocrinol* 1993; 138: 159-166.

21. Kolligs F, Fehmann HC, Göke R, Göke B. Reduction of the incretin effect in rats by the glucagon-like peptide-1 receptor antagonist exendin (9-39)amide. *Diabetes* 1995; 44: 16-19.
- 5 22. Wang Z, Wang RM, Owji AA, Smith DM, Ghatel M, Bloom SR. Glucagon-like peptide-1 is a physiological incretin in rat. *J. Clin. Invest.* 1995; 95: 417-421.
23. Thorens B. Expression cloning of the pancreatic b cell receptor for the gluco-incretin hormone glucagon-like peptide 1. *Proc Natl Acad Sci* 1992;89:8641-4645.
- 10 24. Scrocchi L, Auerbach AB, Joyner AL, Drucker DJ. Diabetes in mice with targeted disruption of the GLP-1 receptor gene. *Diabetes* 1996; 45: 21A.
- 15 25. Fehmann HC, Göke R, Göke B. Cell and molecular biology of the incretin hormones glucagon-like peptide-I (GLP-1) and glucose-dependent insulin releasing polypeptide (GIP). *Endocrine Reviews*, 1995; 16: 390-410.
- 20 26. Gromada J, Dissing S, Bokvist K, Renström E, Frøkjær-Jensen J, Wulff BS, Rorsman P. Glucagon-like peptide I increases cytoplasmic calcium in insulin-secreting bTC3-cells by enhancement of intracellular calcium mobilisation. *Diabetes* 1995; 44: 767-774.
- 25 27. Holz GG, Leech CA, Habener JF. Activation of a cAMP-regulated Ca^{2+} signaling pathway in pancreatic β -cells by the insulinotropic hormone glucagon-like peptide-1. *J Biol Chem*, 1996; 270: 17749-17759.
28. Holz GG, Kühlreiber WM, Habener JF. Pancreatic beta-cells are rendered glucose competent by the insulinotropic hormone glucagon-like peptide-1(7-37). *Nature* 1993;361:362-365.
- 30 29. Ørskov C, Holst JJ, Nielsen OV: Effect of truncated glucagon-like peptide-1 (proglucagon 78-107 amide) on endocrine secretion from pig pancreas, antrum and stomach. *Endocrinology* 1988;123:2009-2013.

30. Hvidberg A, Toft Nielsen M, Hilsted J, Ørskov C, Holst JJ. Effect of glucagon-like peptide-1 (proglucagon 78-107amide) on hepatic glucose production in healthy man. *Metabolism* 1994;43:104-108.
- 5 31. Qualmann C, Nauck M, Holst JJ, Ørskov C, Creutzfeldt W. Insulinotropic actions of intravenous glucagon-like peptide-1 [7-36 amide] in the fasting state in healthy subjects. *Acta Diabetologica*, 1995; 32: 13-16.
- 10 32. Nauck MA, Helmesaat MM, Ørskov C, Holst JJ, Ebert R, Creutzfeldt W. Preserved incretin activity of GLP-1(7-36amide) but not of synthetic human GIP in patients with type 2-diabetes mellitus. *J Clin Invest* 1993;91:301-307.
- 15 33. Nauck MA, Kleine N, Ørskov C, Holst JJ, Willms B, Creutzfeldt W. Normalisation of fasting hyperglycaemia by exogenous GLP-1(7-36amide) in type 2-diabetic patients. *Diabetologia* 1993;36:741-744.
- 20 34. Creutzfeldt W, Kleine N, Willms B, Ørskov C, Holst JJ, Nauck MA. Glucagonostatic actions and reduction of fasting hyperglycaemia by exogenous glucagon-liem, peptide-1(7-36amide) in type I diabetic patients. *Diabetes Care* 1996; 19: 580-586.
35. Schjoldager BTG, Mortensen PE, Christiansen J, Ørskov C, Holst JJ. GLP-1 (glucagon-like peptide-1) and truncated GLP-1, fragments of human proglucagon, inhibit gastric acid secretion in man. *Dig. Dis. Sci.* 1989; 35:703-708.
- 25 36. Wettergren A, Schjoldager B, Mortensen PE, Myhre J, Christiansen J, Holst JJ. Truncated GLP-1 (proglucagon 72-107amide) inhibits gastric and pancreatic functions in man. *Dig Dis Sci* 1993;38:665-673.
- 30 37. Layer P, Holst JJ, Grandt D, Goebell H: Ileal release of glucagon-like peptide-1 (GLP-1): association with inhibition of gastric acid in humans. *Dig Dis Sci* 1995; 40: 1074-1082.
38. Layer P, Holst JJ. GLP-1: A humoral mediator of the ileal brake in humans? *Digestion* 1993; 54: 385-386.

39. Nauck M, Ettler R, Niedereichholz U, Ørskov C, Holst JJ, Schmiegeler W. Inhibition of gastric emptying by GLP-1(7-36 amide) or (7-37): effects on postprandial glycaemia and insulin secretion. Abstract. Gut 1995; 37 (suppl. 2): A124.
- 5 40. Schick RR, vom Walde T, Zimmermann JP, Schusdziarra V, Classen M. Glucagon-like peptide 1 - a novel brain peptide involved in feeding regulation. in Ditschuneit H, Gries FA, Hauner H, Schusdziarra V, Wechsler JG (eds.) Obesity in Europe. John Libbey & Company Ltd, 1994; pp. 363-367.
- 10 41. Tang-Christensen M, Larsen PJ, Göke R, Fink-Jensen A, Jessop DS, Møller M, Sheikh S. Brain GLP-1(7-36) amide receptors play a major role in regulation of food and water intake. Am. J. Physiol., 1996, in press.
- 15 42. Turton MD, O'Shea D, Gunn I, Beak SA, Edwards CMB, Meeran K, et al. A role for glucagon-like peptide-1 in the regulation of feeding. Nature 1996; 379: 69-72.
43. Willms B, Werner J, Creutzfeldt W, Ørskov C, Holst JJ, Nauck M. Inhibition of gastric emptying by glucagon-like peptide-1 (7-36 amide) in patients with type-2-diabetes mellitus. Diabetologia 1994; 37, suppl.1: A118.
- 20 44. Larsen J, Jallad N, Damsbo P. One-week continuous infusion of GLP-1(7-37) improves glycaemic control in NIDDM. Diabetes 1996; 45, suppl. 2: 233A.
- 25 45. Ritzel R, Ørskov C, Holst JJ, Nauck MA. Pharmacokinetic, insulinotropic, and glucagonostatic properties of GLP-1 [7-36 amide] after subcutaneous injection in healthy volunteers. Dose-response relationships. Diabetologia 1995; 38: 720-725.
- 30 46. Deacon CF, Johnsen AH, Holst JJ. Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo. J Clin Endocrinol Metab 1995; 80: 952-957.
- 35 47. Deacon CF, Nauck MA, Toft-Nielsen M, Pridal L, Willms B, Holst JJ. 1995. Both subcutaneous and intravenously administered glucagon-like peptide-1 are rapidly degraded from the amino terminus in type II diabetic patients and in healthy subjects. Diabetes 44: 1126-1131.

SUMMARY OF THE INVENTION

5 The present invention relates to a compound which comprises a therapeutic polypeptide linked to an albumin binding residue via a hydrophilic spacer.

The present invention also relates to a compound which comprises a therapeutic polypeptide linked to an albumin binding residue via a hydrophilic spacer that separates the polypeptide and the albumin binding residue with a chemical moiety comprising at least 5 heavy atoms where 30-50% of these are either N or O.

In one embodiment of this invention the spacer is defined as

$-(CH_2)_l D[(CH_2)_n E]_m (CH_2)_p Q_q-$, wherein

l, m and n independently are 1-20 and p is 0-10,

15 Q is $-Z-(CH_2)_l D[(CH_2)_n G]_m (CH_2)_p-$,

q is 0 or 1,

each D, E, and G independently are selected from $-O-$, $-NR^3-$, $-N(COR^4)-$, $-PR^5(O)-$, and $-P(OR^6)(O)-$, wherein R^3 , R^4 , R^5 , and R^6 independently represent hydrogen or C_{1-6} -alkyl,

20 Z is selected from $-C(O)NH-$, $-C(O)NHCH_2-$, $-OC(O)NH-$, $-C(O)NHCH_2CH_2-$, $-C(O)CH_2-$, $-C(O)CH=CH-$, $-(CH_2)_s-$, $-C(O)-$, $-C(O)O-$ or $-NHC(O)-$, wherein s is 0 or 1

or a pharmaceutically acceptable salt or prodrug thereof.

25 The present invention also relates to a compound which has the formula (I) :



wherein

A is an albumin binding residue,

B is a hydrophilic spacer being $-(CH_2)_l D[(CH_2)_n E]_m (CH_2)_p Q_q-$, wherein

30 l, m and n independently are 1-20 and p is 0-10,

Q is $-Z-(CH_2)_l D[(CH_2)_n G]_m (CH_2)_p-$,

q is 0 or 1,

each D, E, and G independently are selected from $-O-$, $-NR^3-$, $-N(COR^4)-$, $-PR^5(O)-$, and $-P(OR^6)(O)-$, wherein R^3 , R^4 , R^5 , and R^6 independently represent hydrogen or

35 C_{1-6} -alkyl,

Z is selected from $-\text{C}(\text{O})\text{NH}-$, $-\text{C}(\text{O})\text{NHCH}_2-$, $-\text{OC}(\text{O})\text{NH}-$, $-\text{C}(\text{O})\text{NHCH}_2\text{CH}_2-$,
 $-\text{C}(\text{O})\text{CH}_2-$, $-\text{C}(\text{O})\text{CH}=\text{CH}-$, $-(\text{CH}_2)_s-$, $-\text{C}(\text{O})-$, $-\text{C}(\text{O})\text{O}-$ or $-\text{NHC}(\text{O})-$, wherein s is 0 or
 1,

Y is a chemical group linking B and the therapeutic agent, and

5 W is a chemical group linking A and B.

The present invention also relates to a compound which has the formula (II)



wherein

10 A and A' are albumin binding residues,

B and B' are hydrophilic spacers independently selected from $-(\text{CH}_2)_l\text{D}[(\text{CH}_2)_n\text{E}]_m(\text{CH}_2)_p\text{Q}_q-$,

wherein

l, m and n independently are 1-20 and p is 0-10,

Q is $-\text{Z}-(\text{CH}_2)_l\text{D}[(\text{CH}_2)_n\text{G}]_m(\text{CH}_2)_p-$,

15 q is 0 or 1,

each D, E, and G independently are selected from $-\text{O}-$, $-\text{NR}^3-$, $-\text{N}(\text{COR}^4)-$, $-\text{PR}^5(\text{O})-$,
 and $-\text{P}(\text{OR}^6)(\text{O})-$, wherein R^3 , R^4 , R^5 , and R^6 independently represent hydrogen or
 C_{1-6} -alkyl,

Z is selected from $-\text{C}(\text{O})\text{NH}-$, $-\text{C}(\text{O})\text{NHCH}_2-$, $-\text{OC}(\text{O})\text{NH}-$, $-\text{C}(\text{O})\text{NHCH}_2\text{CH}_2-$,
 20 $-\text{C}(\text{O})\text{CH}_2-$, $-\text{C}(\text{O})\text{CH}=\text{CH}-$, $-(\text{CH}_2)_s-$, $-\text{C}(\text{O})-$, $-\text{C}(\text{O})\text{O}-$ or $-\text{NHC}(\text{O})-$, wherein s is 0 or
 1,

Y is a chemical group linking B and the therapeutic agent, and

Y' is a chemical group linking B' and the therapeutic agent, and

W is a chemical group linking A and B, and

25 W' is a chemical group linking A' and B'.

In one embodiment of the invention Y' is selected from the group consisting of -
 $\text{C}(\text{O})\text{NH}-$, $-\text{C}(\text{O})\text{NHCH}_2-$, $-\text{OC}(\text{O})\text{NH}-$, $-\text{C}(\text{O})\text{CH}_2-$, $-\text{C}(\text{O})\text{CH}=\text{CH}-$, $-(\text{CH}_2)_s-$, $-\text{C}(\text{O})-$, $-\text{C}(\text{O})\text{O}-$
 and $-\text{NHC}(\text{O})-$, wherein s is 0 or 1.

30

In a further embodiment of the invention W' is selected from the group consisting of
 $-\text{C}(\text{O})\text{NH}-$, $-\text{C}(\text{O})\text{NHCH}_2-$, $-\text{OC}(\text{O})\text{NH}-$, $-\text{C}(\text{O})\text{CH}_2-$, $-\text{C}(\text{O})\text{CH}=\text{CH}-$, $-(\text{CH}_2)_s-$, $-\text{C}(\text{O})-$, $-\text{C}(\text{O})\text{O}-$
 or $-\text{NHC}(\text{O})-$, wherein s is 0 or 1.

In another aspect the present invention relates to a compound which has the formula

(III)



wherein

5 A and A' are albumin binding residues,

B is a hydrophilic spacer selected from $-(\text{CH}_2)_l\text{D}[(\text{CH}_2)_n\text{E}]_m(\text{CH}_2)_p-\text{Q}_q-$ wherein

l, m and n independently are 1-20 and p is 0-10,

Q is $-\text{Z}-(\text{CH}_2)_l\text{D}[(\text{CH}_2)_n\text{G}]_m(\text{CH}_2)_p-$,

q is 0 or 1,

10 each D, E, and G are independently selected from $-\text{O}-$, $-\text{NR}^3-$, $-\text{N}(\text{COR}^4)-$, $-\text{PR}^5(\text{O})-$,
and $-\text{P}(\text{OR}^6)(\text{O})-$, wherein R^3 , R^4 , R^5 , and R^6 independently represent hydrogen or
 C_{1-6} -alkyl,

Z is selected from $-\text{C}(\text{O})\text{NH}-$, $-\text{C}(\text{O})\text{NHCH}_2-$, $-\text{OC}(\text{O})\text{NH}-$, $-\text{C}(\text{O})\text{NHCH}_2\text{CH}_2-$,

$-\text{C}(\text{O})\text{CH}_2-$, $-\text{C}(\text{O})\text{CH}=\text{CH}-$, $-(\text{CH}_2)_s-$, $-\text{C}(\text{O})-$, $-\text{C}(\text{O})\text{O}-$ or $-\text{NHC}(\text{O})-$, wherein s is 0 or

15 1,

Y is a chemical group linking B and the therapeutic agent, and

W'' is a chemical group linking B with A and A'.

20 In another aspect the present invention relates to a compound comprising a hydrophilic spacer between a therapeutic peptide and one or more albumin binding residue(s), said compound having a protracted profile of action relative to the therapeutic polypeptide, where the albumin binding fraction as well as the free fraction of said compound are both able to bind to the receptor mediating the effect of the therapeutic polypeptide.

25 In one embodiment the hydrophilic spacer is an unbranched oligo ethylene glycol moiety with appropriate functional groups at both terminals that forms a bridge between an amino group of the therapeutic polypeptide and a functional group of the albumin binding residue.

30 In one embodiment Y is selected from the group consisting of $-\text{C}(\text{O})\text{NH}-$, $-\text{C}(\text{O})\text{NHCH}_2-$, $-\text{OC}(\text{O})\text{NH}-$, $-\text{C}(\text{O})\text{NHCH}_2-$, $-\text{C}(\text{O})\text{CH}_2-$, $-\text{C}(\text{O})\text{CH}=\text{CH}-$, $-(\text{CH}_2)_s-$, $-\text{C}(\text{O})-$, $-\text{C}(\text{O})\text{O}-$ and $-\text{NHC}(\text{O})-$, wherein s is 0 or 1.

In another embodiment W is selected from the group consisting of $-\text{C}(\text{O})\text{NH}-$, $-\text{C}(\text{O})\text{NHCH}_2-$, $-\text{OC}(\text{O})\text{NH}-$, $-\text{C}(\text{O})\text{NHCH}_2-$, $-\text{C}(\text{O})\text{CH}_2-$, $-\text{C}(\text{O})\text{CH}=\text{CH}-$, $-(\text{CH}_2)_s-$, $-\text{C}(\text{O})-$, $-\text{C}(\text{O})\text{O}-$ or $-\text{NHC}(\text{O})-$, wherein s is 0 or 1.

In another embodiment W'' is selected from the group consisting of
 $-\text{C}(\text{O})\text{NHCH}-$, $-\text{C}(\text{O})\text{CH}-$, $-(\text{CH}_2)_s\text{CH}-$, and $-\text{NHC}(\text{O})\text{CHNHC}(\text{O})\text{CH}_2\text{O}(\text{CH}_2)_2\text{O}(\text{CH}_2)_2\text{NH}-$
 , wherein s is 0, 1 or 2.

- 5 In another embodiment i is 1 or 2, n and m are independently 1-10 and p is 0-10.
 In another embodiment D is $-\text{O}-$.
 In another embodiment of the invention E is $-\text{O}-$.
 In yet another embodiment of the invention the hydrophilic spacer is
 $-\text{CH}_2\text{O}[(\text{CH}_2)_2\text{O}]_m(\text{CH}_2)_p\text{Q}_q-$, where m is 1-10, p is 1-3, and Q is $-\text{Z}-\text{CH}_2\text{O}[(\text{CH}_2)_2\text{O}]_m(\text{CH}_2)_p-$.
 10 In another embodiment q is 1.
 In another embodiment G is $-\text{O}-$.
 In yet another embodiment of the invention Z is selected from the group consisting of -
 $\text{C}(\text{O})\text{NH}-$, $-\text{C}(\text{O})\text{NHCH}_2-$, and $-\text{OC}(\text{O})\text{NH}-$.
 In yet another embodiment q is 0.
 15 In another embodiment l is 2.
 In another embodiment n is 2.
 In yet another embodiment the hydrophilic spacer B is $-\text{CH}_2\text{CH}_2\text{O}]_{m+1}(\text{CH}_2)_p\text{Q}_q-$.
 In another embodiment the molar weight of said hydrophilic spacer is in the range
 from 80D to 1000D or in the range from 80D to 300D.
 20 In another aspect of the present invention the therapeutic polypeptide is a GLP-1 pep-
 tide.

DEFINITIONS

25 In the present specification, the following terms have the indicated meaning :

The term "albumin binding residue" as used herein means a residue which binds non-covalently to human serum albumin. The albumin binding residue attached to the therapeutic polypeptide typically has an affinity below 10 μM to human serum albumin and preferably below 1 μM . A range of albumin binding residues are known among linear and branched lipophilic moieties containing 4-40 carbon atoms, compounds with a cyclopentanophenanthrene
 30 skeleton, peptides having 10-30 amino acid residues etc.

The term "hydrophilic spacer" as used herein means a spacer that separates a peptide and an albumin binding residue with a chemical moiety which comprises at least 5 heavy atoms where 30-50% of these are either N or O.

The term "therapeutic polypeptide" as used herein means a polypeptide which is being developed for therapeutic use, or which has been developed for therapeutic use.

The term "polypeptide" and "peptide" as used herein means a compound composed of at least five constituent amino acids connected by peptide bonds. The constituent amino acids may be from the group of the amino acids encoded by the genetic code and they may natural amino acids which are not encoded by the genetic code, as well as synthetic amino acids. Natural amino acids which are not encoded by the genetic code are e.g. hydroxyproline, γ -carboxyglutamate, ornithine, phosphoserine, D-alanine and D-glutamine. Synthetic amino acids comprise amino acids manufactured by chemical synthesis, i.e. D-isomers of the amino acids encoded by the genetic code such as D-alanine and D-leucine, Aib (α -aminoisobutyric acid), Abu (α -aminobutyric acid), Tle (tert-butylglycine), β -alanine, 3-aminomethyl benzoic acid, anthranilic acid.

The term "analogue" as used herein referring to a polypeptide means a modified peptide wherein one or more amino acid residues of the peptide have been substituted by other amino acid residues and/or wherein one or more amino acid residues have been deleted from the peptide and/or wherein one or more amino acid residues have been added to the peptide. Such addition or deletion of amino acid residues can take place at the N-terminal of the peptide and/or at the C-terminal of the peptide. Two different and simple systems are often used to describe analogues : For example Arg³⁴-GLP-1(7-37) or K34R-GLP-1(7-37) designates a GLP-1 analogue wherein amino acid residues at position 1-6 have been deleted, and the naturally occurring lysine at position 34 has been substituted with arginine (standard single letter abbreviation for amino acids used according to IUPAC-IUB nomenclature).

The term "derivative" as used herein in relation to a peptide means a chemically modified peptide or an analogue thereof, wherein at least one substituent is not present in the unmodified peptide or an analogue thereof, i.e. a peptide which has been covalently modified. Typical modifications are amides, carbohydrates, alkyl groups, acyl groups, esters and the like. An example of a derivative of GLP-1(7-37) is Arg³⁴, Lys²⁸(N^ε-(γ -Glu(N^α-hexadecanoyl))) -GLP-1(7-37).

The term "GLP-1 peptide" as used herein means GLP-1(7-37), a GLP-1 analogue, a GLP-1 derivative or a derivative of a GLP-1 analogue.

The term "GLP-2 peptide" as used herein means GLP-2(1-33), a GLP-2 analogue, a GLP-2 derivative or a derivative of a GLP-2 analogue.

The term "exendin-4 peptide" as used herein means exendin-4(1-39), an exendin-4 analogue, an exendin-4 derivative or a derivative of an exendin-4 analogue.

The terms "stable exendin-4 peptide" and "stable GLP-1 peptides" as used herein means chemically modified peptides derived from exendin-4(1-39) or GLP-1(7-37), i.e. an analogue or a derivative which exhibits an in vivo plasma elimination half-life of at least 10 hours in man, as determined by the following method. The method for determination of plasma elimination half-life of an exendin-4 peptide or a GLP-1 peptide in man is : The peptide is dissolved in an isotonic buffer, pH 7.4, PBS or any other suitable buffer. The dose is injected peripherally, preferably in the abdominal or upper thigh. Blood samples for determination of active peptide are taken at frequent intervals, and for a sufficient duration to cover the terminal elimination part (e.g. Pre-dose, 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24 (day 2), 36 (day 2), 48 (day 3), 60 (day 3), 72 (day 4) and 84 (day 4) hours post dose). Determination of the concentration of active peptide is performed as described in Wilken et al., Diabetologia 43(51):A143, 2000. Derived pharmacokinetic parameters are calculated from the concentration-time data for each individual subject by use of non-compartmental methods, using the commercially available software WinNonlin Version 2.1 (Pharsight, Cary, NC, USA). The terminal elimination rate constant is estimated by log-linear regression on the terminal log-linear part of the concentration-time curve, and used for calculating the elimination half-life.

The term "DPP-IV protected" as used herein referring to a polypeptide means a polypeptide which has been chemically modified in order to render said compound resistant to the plasma peptidase dipeptidyl aminopeptidase-4 (DPP-IV). The DPP-IV enzyme in plasma is known to be involved in the degradation of several peptide hormones, e.g. GLP-1, GLP-2, Exendin-4 etc. Thus, a considerable effort is being made to develop analogues and derivatives of the polypeptides susceptible to DPP-IV mediated hydrolysis in order to reduce the rate of degradation by DPP-IV.

The term "C₁₋₆-alkyl" as used herein means a saturated, branched, straight or cyclic hydrocarbon group having from 1 to 6 carbon atoms. Representative examples include, but are not limited to, methyl, ethyl, n-propyl, isopropyl, butyl, isobutyl, sec-butyl, *tert*-butyl, n-pentyl, isopentyl, neopentyl, *tert*-pentyl, n-hexyl, isohexyl, cyclohexane and the like.

30 DETAILED DESCRIPTION OF THE INVENTION

In one embodiment of the invention, the albumin binding residue is a lipophilic residue.

In another embodiment the albumin binding residue is negatively charged at physiological pH. In another embodiment the albumin binding residue comprises a group which can

be negatively charged. One preferred group which can be negatively charged is a carboxylic acid group.

In another embodiment of the invention, the albumin binding residue binds non-covalently to albumin. In another embodiment the albumin binding residue has a binding affinity towards human serum albumin that is below about 10 μ M or below about 1 μ M.

In yet another embodiment of the invention the albumin binding residue is selected from a straight chain alkyl group, a branched alkyl group, a group which has an ω -carboxylic acid group, a partially or completely hydrogenated cyclopentanophenanthrene skeleton.

In another embodiment the albumin binding residue is a cibacronyl residue.

In another embodiment the albumin binding residue has from 6 to 40 carbon atoms, from 8 to 26 carbon atoms or from 8 to 20 carbon atoms.

In another embodiment the albumin binding residue is an acyl group selected from the group comprising $\text{CH}_3(\text{CH}_2)_r\text{CO}-$, wherein r is an integer from 4 to 38, preferably an integer from 4 to 24, more preferred selected from the group comprising $\text{CH}_3(\text{CH}_2)_8\text{CO}-$, $\text{CH}_3(\text{CH}_2)_{10}\text{CO}-$, $\text{CH}_3(\text{CH}_2)_{12}\text{CO}-$, $\text{CH}_3(\text{CH}_2)_{14}\text{CO}-$, $\text{CH}_3(\text{CH}_2)_{16}\text{CO}-$, $\text{CH}_3(\text{CH}_2)_{18}\text{CO}-$, $\text{CH}_3(\text{CH}_2)_{20}\text{CO}-$ and $\text{CH}_3(\text{CH}_2)_{22}\text{CO}-$.

In another embodiment the albumin binding residue is an acyl group of a straight-chain or branched alkane α,ω -dicarboxylic acid.

In another embodiment the albumin binding residue is an acyl group selected from the group comprising $\text{HOOC}(\text{CH}_2)_s\text{CO}-$, wherein s is an integer from 4 to 38, preferably an integer from 4 to 24, more preferred selected from the group comprising $\text{HOOC}(\text{CH}_2)_{14}\text{CO}-$, $\text{HOOC}(\text{CH}_2)_{16}\text{CO}-$, $\text{HOOC}(\text{CH}_2)_{18}\text{CO}-$, $\text{HOOC}(\text{CH}_2)_{20}\text{CO}-$ and $\text{HOOC}(\text{CH}_2)_{22}\text{CO}-$.

In another embodiment the albumin binding residue is a group of the formula $\text{CH}_3(\text{CH}_2)_t((\text{CH}_2)_u\text{COOH})\text{CHNH-CO}(\text{CH}_2)_2\text{CO}-$, wherein t and u are integers and t+u is an integer of from 8 to 33, preferably from 12 to 28.

In another embodiment the albumin binding residue is a group of the formula $\text{CH}_3(\text{CH}_2)_v\text{CO-NHCH}(\text{COOH})(\text{CH}_2)_2\text{CO}-$, wherein v is an integer of from 10 to 24.

In another embodiment the albumin binding residue is a group of the formula $\text{CH}_3(\text{CH}_2)_w\text{CO-NHCH}((\text{CH}_2)_2\text{COOH})\text{CO}-$, wherein w is an integer of from 8 to 24.

In another embodiment the albumin binding residue is a group of the formula $\text{COOH}(\text{CH}_2)_x\text{CO}-$ wherein x is an integer of from 8 to 24.

In another embodiment the albumin binding residue is a group of the formula $-\text{NHCH}(\text{COOH})(\text{CH}_2)_4\text{NH-CO}(\text{CH}_2)_y\text{CH}_3$, wherein y is an integer of from 8 to 18.

In another embodiment the albumin binding residue is a group of the formula
 $\text{-NHCH(COOH)(CH}_2\text{)}_4\text{NH-COCH((CH}_2\text{)}_2\text{COOH)NH-CO(CH}_2\text{)}_z\text{CH}_3$, wherein z is an integer of
 from 10 to 16.

5 In another embodiment the albumin binding residue is a group of the formula
 $\text{-NHCH(COOH)(CH}_2\text{)}_4\text{NH-CO(CH}_2\text{)}_2\text{CH(COOH)NH-CO(CH}_2\text{)}_a\text{CH}_3$, wherein a is an integer of
 from 10 to 16.

In another embodiment the albumin binding residue is a group of the formula
 $\text{-NHCH(COOH)(CH}_2\text{)}_4\text{NH-CO(CH}_2\text{)}_2\text{CH(COOH)NHCO(CH}_2\text{)}_b\text{CH}_3$, wherein b is zero or an inte-
 ger of from 1 to 22.

10 In another embodiment of the invention the albumin binding residue is a peptide, such
 as a peptide comprising less than 40 amino acid residues. A number of small peptides which
 are albumin binding residues as well as a method for their identification is found in J. Biol
 Chem. 277, 38 (2002) 35035-35043.


15 In another embodiment of the invention the albumin binding residue is attached to
 said therapeutic polypeptide via the ϵ -amino group of a lysine residue.

In another embodiment the albumin binding residue is attached to said therapeutic
 polypeptide via an amino acid residue selected from cysteine, glutamate and aspartate.

20 Human GLP-1 is a 37 amino acid residue peptide originating from preproglucagon
 which is synthesised *i.a.* in the L-cells in the distal ileum, in the pancreas and in the brain.
 Processing of preproglucagon to give GLP-1(7-36)amide, GLP-1(7-37) and GLP-2 occurs
 mainly in the L-cells. A simple system is used to describe fragments and analogues of this pep-
 tide. Thus, for example, Gly⁸-GLP-1(7-37) designates a fragment of GLP-1 formally derived
 from GLP-1 by deleting the amino acid residues Nos. 1 to 6 and substituting the naturally oc-
 25 ccurring amino acid residue in position 8 (Ala) by Gly. Similarly, Lys³⁴(N ^{ϵ} -tetradecanoyl)-GLP-
 1(7-37) designates GLP-1(7-37) wherein the ϵ -amino group of the Lys residue in position 34
 has been tetradecanoylated. Where reference in this text is made to C-terminally extended
 GLP-1 analogues, the amino acid residue in position 38 is Arg unless otherwise indicated, the
 optional amino acid residue in position 39 is also Arg unless otherwise indicated and the op-
 30 tional amino acid residue in position 40 is Asp unless otherwise indicated. Also, if a C-
 terminally extended analogue extends to position 41, 42, 43, 44 or 45, the amino acid se-
 quence of this extension is as in the corresponding sequence in human preproglucagon unless
 otherwise indicated.

In one embodiment of the present invention the therapeutic polypeptide is a GLP-1 peptide.

In another embodiment of the invention the therapeutic polypeptide is a GLP-1 peptide comprising the amino acid sequence of the formula (IV):



Formula (IV) (SEQ ID No: 2)

wherein

- 10 Xaa₇ is L-histidine, D-histidine, desamino-histidine, 2-amino-histidine, β -hydroxy-histidine, homohistidine, N^o-acetyl-histidine, α -fluoromethyl-histidine, α -methyl-histidine, 3-pyridylalanine, 2-pyridylalanine or 4-pyridylalanine;

Xaa₈ is Ala, Gly, Val, Leu, Ile, Lys, Aib or (1-aminocycloalkyl) carboxylic acid;

Xaa₁₆ is Val or Leu;

- 15 Xaa₁₈ is Ser, Lys or Arg;

Xaa₁₉ is Tyr or Gln;

Xaa₂₀ is Leu or Met;

Xaa₂₂ is Gly, Glu or Aib;

Xaa₂₃ is Gln, Glu, Lys or Arg;

- 20 Xaa₂₅ is Ala or Val;

Xaa₂₆ is Lys, Glu or Arg;

Xaa₂₇ is Glu or Leu;

Xaa₃₀ is Ala, Glu or Arg;

Xaa₃₃ is Val or Lys;

- 25 Xaa₃₄ is Lys, Glu, Asn or Arg;

Xaa₃₅ is Gly or Aib;

Xaa₃₆ is Arg, Gly or Lys;

Xaa₃₇ is Gly, Ala, Glu, Pro or Lys;

Xaa₃₈ is Lys, Ser, NH₂ or is absent.

- 30 Xaa₃₉ is Ser, Lys or is absent;

Xaa₄₀ is Gly or is absent;

Xaa₄₁ is Ala or is absent;

Xaa₄₂ is Pro or is absent;

Xaa₄₃ is Pro or is absent;

- 35 Xaa₄₄ is Pro or is absent;

Xaa₄₅ is Ser or is absent;

Xaa₄₆ is NH₂ or is absent ;

provided that if Xaa₃₈, Xaa₃₉, Xaa₄₀, Xaa₄₁, Xaa₄₂, Xaa₄₃, Xaa₄₄, Xaa₄₅ or Xaa₄₆ is absent then each amino acid residue downstream is also absent.

5

In another embodiment of the invention the polypeptide is a GLP-1 peptide comprising the amino acid sequence of formula (V):

Xaa₇-Xaa₈-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Xaa₁₈-Tyr-Leu-Glu-Xaa₂₂-Xaa₂₃-Ala-Ala-Xaa₂₆-Glu-Phe-Ile-Xaa₃₀-Trp-Leu-Val-Xaa₃₄-Xaa₃₅-Xaa₃₆-Xaa₃₇-Xaa₃₈

10

Formula (V) (SEQ ID No: 3)

wherein

Xaa₇ is L-histidine, D-histidine, desamino-histidine, 2-amino-histidine, β -hydroxy-histidine, homohistidine, N^ε-acetyl-histidine, α -fluoromethyl-histidine, α -methyl-histidine, 3-pyridylalanine, 2-pyridylalanine or 4-pyridylalanine;

15

Xaa₈ is Ala, Gly, Val, Leu, Ile, Lys, Aib or (1-aminocycloalkyl) carboxylic acid;

Xaa₁₈ is Ser, Lys or Arg;

Xaa₂₂ is Gly, Glu or Aib;

Xaa₂₃ is Gln, Glu, Lys or Arg;

Xaa₂₆ is Lys, Glu or Arg;

20

Xaa₃₀ is Ala, Glu or Arg;

Xaa₃₄ is Lys, Glu or Arg;

Xaa₃₅ is Gly or Aib;

Xaa₃₆ is Arg or Lys;

Xaa₃₇ is Gly, Ala, Glu or Lys;

25

Xaa₃₈ is Lys, NH₂ or is absent.

In yet another embodiment of the invention the GLP-1 peptide is selected from GLP-1(7-35), GLP-1(7-36), GLP-1(7-36)-amide, GLP-1(7-37), GLP-1(7-38), GLP-1(7-39), GLP-1(7-40), GLP-1(7-41) or an analogue thereof.

30

In another embodiment the GLP-1 peptide is a fragment of a peptide selected from the group comprising GLP-1(7-35), GLP-1(7-36), GLP-1(7-36)amide, GLP-1(7-37), GLP-1(7-38), GLP-1(7-39), GLP-1(7-40) and GLP-1(7-41) or an analogue thereof.

In another embodiment of the invention the GLP-1 peptide is GLP-1(A-B) wherein A is an integer from 1 to 7 and B is an integer from 38 to 45 or an analogue thereof comprising one albumin binding residue attached via a hydrophilic spacer to the C-terminal amino acid residue

35

and, optionally, a second albumin binding residue attached to one of the other amino acid residues.

In another embodiment the GLP-1 peptide comprises no more than fifteen amino acid residues which have been exchanged, added or deleted as compared to GLP-1(7-37) (SEQ ID No. 1), or no more than ten amino acid residues which have been exchanged, added or deleted as compared to GLP-1(7-37) (SEQ ID No. 1).

In another embodiment the GLP-1 peptide comprises no more than six amino acid residues which have been exchanged, added or deleted as compared to GLP-1(7-37) (SEQ ID No. 1).

In another embodiment the GLP-1 peptide comprises no more than 4 amino acid residues which are not encoded by the genetic code.

In another embodiment the GLP-1 peptide is a DPPIV protected GLP-1 peptide.

In another embodiment the GLP-1 peptide comprises an Aib residue in position 8.

In another embodiment the amino acid residue in position 7 of said GLP-1 peptide is selected from the group consisting of D-histidine, desamino-histidine, 2-amino-histidine, β -hydroxy-histidine, homohistidine, N^α-acetyl-histidine, α -fluoromethyl-histidine, α -methyl-histidine, 3-pyridylalanine, 2-pyridylalanine and 4-pyridylalanine.

In another embodiment the GLP-1 peptide is selected from the group consisting of Arg³⁴GLP-1(7-37), Arg³⁴GLP-1(7-37)-OH,

Lys³⁸Arg^{26,34}GLP-1(7-38), Lys³⁸Arg^{26,34}GLP-1(7-38)-OH, Lys³⁶Arg^{26,34}GLP-1(7-36),

Lys³⁶Arg^{26,34}GLP-1(7-36)-OH, Aib^{8,22,35}GLP-1(7-37), Aib^{8,35}GLP-1(7-37), Aib^{8,22}GLP-1(7-37),

Aib^{8,22,35}GLP-1(7-37)-OH, Aib^{8,35}GLP-1(7-37)-OH, Aib^{8,22}GLP-1(7-37)-OH,

Aib^{8,22,35}Arg^{26,34}Lys³⁸GLP-1(7-38)-OH, Aib^{8,35}Arg^{26,34}Lys³⁸GLP-1(7-38)-OH,

Aib^{8,22}Arg^{26,34}Lys³⁸GLP-1(7-38)-OH, Aib^{8,22,35}Arg^{26,34}Lys³⁸GLP-1(7-38),

Aib^{8,35}Arg^{26,34}Lys³⁸GLP-1(7-38), Aib^{8,22}Arg^{26,34}Lys³⁸GLP-1(7-38),

Aib^{8,22,35}Arg^{26,34}Lys³⁸GLP-1(7-38)-OH, Aib^{8,35}Arg^{26,34}Lys³⁸GLP-1(7-38)-OH,

Aib^{8,22}Arg^{26,34}Lys³⁸GLP-1(7-38)-OH, Aib^{8,22,35}Arg²⁶Lys³⁸GLP-1(7-38),

Aib^{8,35}Arg²⁶Lys³⁸GLP-1(7-38), Aib^{8,22}Arg²⁶Lys³⁸GLP-1(7-38),

Aib^{8,22,35}Arg²⁶Lys³⁸GLP-1(7-38)-OH, Aib^{8,35}Arg²⁶Lys³⁸GLP-1(7-38)-OH,

Aib^{8,22}Arg²⁶Lys³⁸GLP-1(7-38)-OH, Aib^{8,22,35}Arg³⁴Lys³⁸GLP-1(7-38),

Aib^{8,35}Arg³⁴Lys³⁸GLP-1(7-38), Aib^{8,22}Arg³⁴Lys³⁸GLP-1(7-38),

Aib^{8,22,35}Arg³⁴Lys³⁸GLP-1(7-38)-OH, Aib^{8,35}Arg³⁴Lys³⁸GLP-1(7-38)-OH,

Aib^{8,22}Arg³⁴Lys³⁸GLP-1(7-38)-OH, Aib^{8,22,35}Ala³⁷Lys³⁸GLP-1(7-38), Aib^{8,35}Ala³⁷Lys³⁸GLP-1(7-38),

Aib^{8,22}Ala³⁷Lys³⁸GLP-1(7-38), Aib^{8,22,35}Ala³⁷Lys³⁸GLP-1(7-38)-OH,

Aib^{8,35}Ala³⁷Lys³⁸GLP-1(7-38)-OH, Aib^{8,22}Ala³⁷Lys³⁸GLP-1(7-38)-OH, Aib^{8,22,35}Lys³⁷GLP-1(7-37),
 Aib^{8,35}Lys³⁷GLP-1(7-37), Aib^{8,22}Lys³⁷GLP-1(7-38), Aib^{8,22,35}Lys³⁷GLP-1(7-37)-OH,
 Aib^{8,35}Lys³⁷GLP-1(7-37)-OH, and Aib^{8,22}Lys³⁷GLP-1(7-38)-OH,

In another embodiment the GLP-1 peptide is attached to said hydrophilic spacer via
 5 the amino acid residue in position 23, 26, 34, 36 or 38 relative to the amino acid sequence
 SEQ ID No:1.

In another embodiment the GLP-1 peptide is exendin-4.

In another embodiment the GLP-1 peptide is ZP-10, i.e. HEGT-
 FTSDLSKQMEEEAVRLFIEWLKNGGPSSGAPPSKKKKKK-NH₂.

10 In another embodiment the GLP-1 peptide is
 HEGTFTSDLSKQMEEEAVRLFIEWLKNGGX, wherein X = P or Y, or a fragment or an ana-
 logue thereof.

In another embodiment the parent peptide is
 DLSKQMEEEAVRLFIEWLKNGGPSSGAPPPS, or a fragment or an analogue thereof.

15 In another embodiment of the invention the compound is
 Arg¹⁸, Leu²⁰, Gln³⁴, Lys³³ (N^ε-(γ-aminobutyroyl(N^α-hexadecanoyl))) Exendin-4-(7-45)-NH₂ or
 Arg³³, Leu²⁰, Gln³⁴, Lys¹⁸ (N^ε-(γ-aminobutyroyl(N^α-hexadecanoyl))) Exendin-4-(7-45)-NH₂.

In another embodiment of the invention one albumin binding residue is attached to the
 20 C-terminal amino acid residue of the GLP-1 peptide via the hydrophilic spacer.

In another embodiment of the invention a second albumin binding residue is attached
 to an amino acid residue which is not the C-terminal amino acid residue of the GLP-1 peptide.

In another embodiment, the lipophilic substituent is attached to the GLP-1 peptide by
 means of a hydrophilic spacer in such a way that a carboxyl group of the spacer forms an am-
 25 ide bond with an amino group of the GLP-1 peptide.

In another embodiment of the invention the compound is selected from the group con-
 sisting of

N^{ε37}-(2-(2-(2-(dodecylamino)ethoxy)ethoxy)acetyl)-[Aib^{8,22,35}] GLP-1 H-(7-37)-NH₂,

N^{ε37}-(2-(2-(2-(17-sulphohexadecanoylamino)ethoxy)ethoxy)acetyl)-[Aib^{8,22,35},Lys³⁷] GLP-1

30 H-(7-37)-NH₂,

N^{ε37}-(2-[2-(2-(15-carboxyhexadecanoylamino)ethoxy)ethoxy]acetyl)-[Aib^{8,22,35},Lys³⁷] GLP-1


H-(7-37)-NH₂,

N^{ε37}-(2-(2-(2-(17-carboxyheptadecanoylamino)ethoxy)ethoxy)acetyl)-[Aib^{8,22,35},Lys³⁷] GLP-1 H




(7-37)-NH₂.

- N^{ε37}-(2-(2-(2-(19-carboxynonadecanoylamino)ethoxy)ethoxy)acetyl)[Aib^{8,22,35},Lys³⁷]GLP-1 H
(7-37)-NH₂,
- N^{ε38}-(4-(hexadecanoylamino)-4(S)-carboxybutyryl)-[Aib^{8,22,35},Arg^{26,34}] GLP-1 H-(7-37) Lys
NH₂,
- 5 N^{ε38}-(2-(2-(2-(hexadecanoylamino)ethoxy)ethoxy)acetyl)-[Aib^{8,22,35},Arg^{26,34}] GLP-1 H-(7-
37)Lys NH₂,
- N^{ε37}(2-[2-(2,6-(S)-Bis-{2-[2-(2-
(dodecanoylamino)ethoxy)ethoxy]acetyl amino}hexanoylamino)ethoxy]ethoxy))
acetyl-[Aib^{8,22,35}]GLP-1 H-(7-37)-NH₂,
- 10 N^{ε37}-(2-[2-(2,6-(S)-Bis-{2-[2-(2-
(tetradecanoylamino)ethoxy)ethoxy]acetyl amino}hexanoylamino)ethoxy]ethoxy))
acetyl-[Aib^{8,22,35}]GLP-1 H-(7-37)-NH₂,
- N^{ε38}-epsilon38-(2-(2-(2-(4-(hexadecanoylamino)-4(S)-
carboxybutyrylamino)ethoxy)ethoxy)acetyl)-[Aib^{8,22,35},Arg^{26,34}] GLP-1 H-(7-37) Lys-OH,
- 15 N^{ε38}-(2-[2-[4-[4-(4-Amino-9,10-dioxo-3-sulfo-9,10-dihydro-anthracen-1-ylamino)-2-sulfo-
phenylamino]-6-(2-sulfo-phenylamino)-[1,3,5]triazin-2-ylamino]-ethoxy]-ethoxy)-acetyl)-
[Aib^{8,22,35}] GLP-1 H (7-37)Lys-NH₂,
- N^{ε38}-({2-[2-(2-[2-[2-(2-[2-(15-carboxypentadecanoylamino)-
ethoxy]ethoxy)acetyl amino]ethoxy]ethoxy)acetyl amino]ethoxy]ethoxy)acetyl)- [Aib^{8,22,35}]
20 GLP-1 H (7-37)Lys- NH₂,
- N^{ε38}-([2-(2-[3-[2,5-dioxo-3-(15-carboxypentadecylsulfanyl)-pyrrolidin-1-yl]-
propionylamino]ethoxy)ethoxy)acetyl]-[D-Ala⁸,Lys³⁷]-GLP-1-[7-37]NH₂,
- N^{ε38}-(2-(2-(2-(11-(oxalylamino)undecanoylamino)ethoxy)ethoxy)acetyl)-) [Aib^{8,22,35},
Ala³⁷,Lys³⁸] GLP-1 H-(7-37)Lys-NH₂,
- 25 N^{ε38}(({2-[2-(2-[2-(2-(15-carboxy-pentadecanoylamino)-
ethoxy]ethoxy)acetyl amino]ethoxy]ethoxy)acetyl)[Aib^{8,22,35},Ala³⁷]-GLP-1[7-37]Lys NH₂,
- N^{ε38}-((2-[2-[11-(5-Dimethylaminonaphthalene-1-
sulfonylamino)undecanoylamino]ethoxy]ethoxy)acetyl [Aib^{8,22,35},Ala³⁷]-GLP-1[7-37]LysNH₂,
- 30 yl]acetyl amino]ethoxy)ethoxy]acetyl) [Aib^{8,22,35},Ala³⁷]-GLP-1(7-37)Lys-NH₂,
- N^{ε38}-2-(2-(2-(octadecanoylamino)ethoxy)ethoxy)acetyl [Aib⁸,Arg^{26,34},Glu^{22,23,30}]GLP-1 H(7-
37)Lys-NH₂,
- N^{ε38}-2-(2-(2-(eicosanoylamino)ethoxy)ethoxy)acetyl [Aib⁸,Arg^{26,34},Glu^{22,23,30}]GLP-1 H(7-
37)Lys-NH₂,

Gly8,Arg26,34,36,Lys38 (N-epsilon({2-[2-(2-{2-[2-(4-Carboxy-4-octadecanoylamino-butrylamino)ethoxy]ethoxy}acetyl)amino)ethoxy]ethoxy}-acetic acid))GLP-1 (7-38),



5 Aib8,Lys38-(N-epsilon-2-(2-(2-(gamma-glutamyl(N-alfa-hexadecanoyl))aminoethoxy)ethoxy)acetyl)-GLP-1 (7-38),



10 Aib8,Lys38-(N-epsilon-2-(2-(2-(2-(2-(2-(gamma-glutamyl(N-alfa-hexadecanoyl))aminoethoxy)ethoxy)acetyl)aminoethoxy)ethoxy)acetyl)-GLP-1 (7-38),

[Aib8,22,35,Lys(C12oyl-Aminoethoxy-ethoxyAcetyl-)]37] GLP-1 H-(7-37)-NH2,

Aib8,22,35,Lys(N-epsilon-C14oyl-aminoethoxyethoxyacetyl-)]37] GLP-1 -(7-37)-NH2,

[Aib8,22,35,Lys(C16oyl-Aminoethoxy-ethoxyAcetyl-)]37] GLP-1 H-(7-37)-NH2,

15 [Aib8,22,35,Lys(C18oyl-Aminoethoxy-ethoxyAcetyl-)]37] GLP-1 H-(7-37)-NH2 and

[Aib8,22,35,Lys(C20oyl-Aminoethoxy-ethoxyAcetyl-)]37] GLP-1 H-(7-37)-NH2.

In another embodiment the therapeutic polypeptide is a GLP-2 peptide.

In another embodiment the GLP-2 peptide is a DPPIV-protected GLP-2 peptide.

20

In another embodiment the GLP-2 peptide is Gly²-GLP-2(1-33).

In yet another embodiment the GLP-2 peptide is Lys¹⁷Arg³⁰-GLP-2(1-33).

In another embodiment of the invention the therapeutic polypeptide is human insulin or an analogue thereof.

5 In another embodiment of the invention the therapeutic polypeptide is selected from the group consisting of Asp^{B28}-human insulin, Lys^{B28},Pro^{B29}-human insulin, Lys^{B3},Glu^{B20}-human insulin, Gly^{A21},Arg^{B31},Arg^{B32}-human insulin and des(B30) human insulin.

In another embodiment of the invention the therapeutic polypeptide is human growth hormone or an analogue thereof.

10 In another embodiment of the invention the therapeutic polypeptide is parathyroid hormone or an analogue thereof.

In another embodiment of the invention the therapeutic polypeptide is human follicle stimulating hormone or an analogue thereof.

15 In another embodiment of the invention the therapeutic polypeptide has a molar weight of less than 100 kDa, less than 50 kDa, or less than 10 kDa.

In another embodiment of the invention the therapeutic polypeptide is selected from the group consisting of a growth factor such as platelet-derived growth factor (PDGF), transforming growth factor α (TGF- α), transforming growth factor β (TGF- β), epidermal growth factor (EGF), vascular endothelial growth factor (VEGF), a somatomedin such as insulin growth factor I (IGF-I), insulin growth factor II (IGF-II), erythropoietin (EPO), thrombopoietin (TPO) or
20 angiopoietin, interferon, pro-urokinase, urokinase, tissue plasminogen activator (t-PA), plasminogen activator inhibitor 1, plasminogen activator inhibitor 2, von Willebrandt factor, a cytokine, e.g. an interleukin such as interleukin (IL) 1, IL-1Ra, IL-2, IL-4, IL-5, IL-6, IL-9, IL-11, IL-12, IL-13, IL-15, IL-16, IL-17, IL-18, IL-20 or IL-21, a colony stimulating factor (CSF) such as GM-
25 CSF, stem cell factor, a tumor necrosis factor such as TNF- α , lymphotoxin- α , lymphotoxin- β , CD40L, or CD30L, a protease inhibitor e.g. aprotinin, an enzyme such as superoxide dismutase, asparaginase, arginase, arginine deaminase, adenosine deaminase, ribonuclease, catalase, uricase, bilirubin oxidase, trypsin, papain, alkaline phosphatase, β -glucuronidase, purine nucleoside phosphorylase or batroxobin, an opioid, e.g. endorphins, enkephalins or non-natural
30 opioids, a hormone or neuropeptide, e.g. calcitonin, glucagon, gastrins, adrenocorticotrophic hormone (ACTH), cholecystokinins, luteinizing hormone, gonadotropin-releasing hormone, chorionic gonadotropin, corticotrophin-releasing factor, vasopressin, oxytocin, antidiuretic hormones, thyroid-stimulating hormone, thyrotropin-releasing hormone, relaxin, prolactin, peptide YY, neuropeptide Y, pancreatic polypeptide, leptin, CART (cocaine and amphetamine regulated transcript), a CART related peptide, perilipin, melanocortins (melanocyte-stimulating hor-
35

mones) such as MC-4, melanin-concentrating hormones, natriuretic peptides, adrenomedullin, endothelin, secretin, amylin, vasoactive intestinal peptide (VIP), pituitary adenylate cyclase activating polypeptide (PACAP), bombesin, bombesin-like peptides, thymosin, heparin-binding protein, soluble CD4, hypothalamic releasing factor, melanotonins and analogues thereof.

5

In another aspect the present invention relates to a pharmaceutical composition comprising a compound according to the invention, and a pharmaceutically acceptable excipient.

In one embodiment the pharmaceutical composition is suited for parenteral administration.

10

In another aspect the present invention relates to the use of a compound according to the invention for the preparation of a medicament.

In one embodiment of the invention a compound according to the invention wherein the therapeutic polypeptide is a GLP-1 peptide is used for the preparation of a medicament for the treatment or prevention of hyperglycemia, type 2 diabetes, impaired glucose tolerance, type 1 diabetes, obesity, hypertension, syndrome X, dyslipidemia, β -cell apoptosis, β -cell deficiency, myocardial infarction, inflammatory bowel syndrome, dyspepsia, cognitive disorders, and cardiovascular disorders.

In another embodiment of the invention a compound according to the invention wherein the therapeutic polypeptide is a GLP-2 peptide is used for the preparation of a medicament for the treatment of small bowel syndrome, inflammatory bowel syndrome or Crohns disease.

In another embodiment of the invention a compound according to the invention wherein the therapeutic polypeptide is an insulin peptide is used for the preparation of a medicament for the treatment or prevention of hyperglycemia, type 1 diabetes, type 2 diabetes or β -cell deficiency.

The therapeutic polypeptide can be produced by a method which comprises culturing a host cell containing a DNA sequence encoding the polypeptide and capable of expressing the polypeptide in a suitable nutrient medium under conditions permitting the expression of the peptide, after which the resulting peptide is recovered from the culture.

30

The medium used to culture the cells may be any conventional medium suitable for growing the host cells, such as minimal or complex media containing appropriate supplements. Suitable media are available from commercial suppliers or may be prepared according to published

35

recipes (e.g. in catalogues of the American Type Culture Collection). The peptide produced by the cells may then be recovered from the culture medium by conventional procedures including separating the host cells from the medium by centrifugation or filtration, precipitating the proteinaceous components of the supernatant or filtrate by means of a salt, e.g. ammonium sulphate, purification by a variety of chromatographic procedures, e.g. ion exchange chromatography, gel filtration chromatography, affinity chromatography, or the like, dependent on the type of peptide in question.

The DNA sequence encoding the therapeutic polypeptide may suitably be of genomic or cDNA origin, for instance obtained by preparing a genomic or cDNA library and screening for DNA sequences coding for all or part of the polypeptide by hybridisation using synthetic oligonucleotide probes in accordance with standard techniques (see, for example, Sambrook, J, Fritsch, EF and Maniatis, T, *Molecular Cloning: A Laboratory Manual*, Cold Spring Harbor Laboratory Press, New York, 1989). The DNA sequence encoding the polypeptide may also be prepared synthetically by established standard methods, e.g. the phosphoramidite method described by Beaucage and Caruthers, *Tetrahedron Letters* 22 (1981), 1859 - 1869, or the method described by Matthes *et al.*, *EMBO Journal* 3 (1984), 801 - 805. The DNA sequence may also be prepared by polymerase chain reaction using specific primers, for instance as described in US 4,683,202 or Saiki *et al.*, *Science* 239 (1988), 487 - 491.

The DNA sequence may be inserted into any vector which may conveniently be subjected to recombinant DNA procedures, and the choice of vector will often depend on the host cell into which it is to be introduced. Thus, the vector may be an autonomously replicating vector, i.e. a vector which exists as an extrachromosomal entity, the replication of which is independent of chromosomal replication, e.g. a plasmid. Alternatively, the vector may be one which, when introduced into a host cell, is integrated into the host cell genome and replicated together with the chromosome(s) into which it has been integrated.

The vector is preferably an expression vector in which the DNA sequence encoding the peptide is operably linked to additional segments required for transcription of the DNA, such as a promoter. The promoter may be any DNA sequence which shows transcriptional activity in the host cell of choice and may be derived from genes encoding proteins either homologous or heterologous to the host cell. Examples of suitable promoters for directing the transcription of the DNA encoding the peptide of the invention in a variety of host cells are well known in the art, cf. for instance Sambrook *et al.*, *supra*.

The DNA sequence encoding the peptide may also, if necessary, be operably connected to a suitable terminator, polyadenylation signals, transcriptional enhancer sequences, and translational enhancer sequences. The recombinant vector of the invention may further comprise a DNA sequence enabling the vector to replicate in the host cell in question.

The vector may also comprise a selectable marker, e.g. a gene the product of which complements a defect in the host cell or one which confers resistance to a drug, e.g. ampicillin, kanamycin, tetracyclin, chloramphenicol, neomycin, hygromycin or methotrexate.

To direct a parent peptide of the present invention into the secretory pathway of the host cells, a secretory signal sequence (also known as a leader sequence, prepro sequence or pre sequence) may be provided in the recombinant vector. The secretory signal sequence is joined to the DNA sequence encoding the peptide in the correct reading frame. Secretory signal sequences are commonly positioned 5' to the DNA sequence encoding the peptide. The secretory signal sequence may be that normally associated with the peptide or may be from a gene encoding another secreted protein.

The procedures used to ligate the DNA sequences coding for the present peptide, the promoter and optionally the terminator and/or secretory signal sequence, respectively, and to insert them into suitable vectors containing the information necessary for replication, are well known to persons skilled in the art (cf., for instance, Sambrook *et al.*, *supra*).

The host cell into which the DNA sequence or the recombinant vector is introduced may be any cell which is capable of producing the present peptide and includes bacteria, yeast, fungi and higher eukaryotic cells. Examples of suitable host cells well known and used in the art are, without limitation, *E. coli*, *Saccharomyces cerevisiae*, or mammalian BHK or CHO cell lines.

Examples of compounds which can be useful as GLP-1 moieties according to the present invention are described in International Patent Application No. WO 87/06941 (The General Hospital Corporation) which relates to a peptide fragment which comprises GLP-1(7-37) and functional derivatives thereof and to its use as an insulinotropic agent.

Further GLP-1 analogues are described in International Patent Application No. 90/11296 (The General Hospital Corporation) which relates to peptide fragments which comprise GLP-1(7-36)

and functional derivatives thereof and have an insulintropic activity which exceeds the insulintropic activity of GLP-1(1-36) or GLP-1(1-37) and to their use as insulintropic agents.

International Patent Application No. 91/11457 (Buckley *et al.*) discloses analogues of the active GLP-1 peptides 7-34, 7-35, 7-36, and 7-37 which can also be useful as GLP-1 moieties according to the present invention.

Pharmaceutical compositions

Pharmaceutical compositions containing a compound according to the present invention may be prepared by conventional techniques, e.g. as described in Remington's *Pharmaceutical Sciences*, 1985 or in Remington: *The Science and Practice of Pharmacy*, 19th edition, 1995.

One object of the present invention is to provide a pharmaceutical formulation comprising a compound according to the present invention which is present in a concentration from about 0.1 mg/ml to about 25 mg/ml, and wherein said formulation has a pH from 2.0 to 10.0. The formulation may further comprise a buffer system, preservative(s), isotonicity agent(s), chelating agent(s), stabilizers and surfactants. In one embodiment of the invention the pharmaceutical formulation is an aqueous formulation, i.e. formulation comprising water. Such formulation is typically a solution or a suspension. In a further embodiment of the invention the pharmaceutical formulation is an aqueous solution. The term "aqueous formulation" is defined as a formulation comprising at least 50 %w/w water. Likewise, the term "aqueous solution" is defined as a solution comprising at least 50 %w/w water, and the term "aqueous suspension" is defined as a suspension comprising at least 50 %w/w water.

In another embodiment the pharmaceutical formulation is a freeze-dried formulation, whereto the physician or the patient adds solvents and/or diluents prior to use.

In another embodiment the pharmaceutical formulation is a dried formulation (e.g. freeze-dried or spray-dried) ready for use without any prior dissolution.

In a further aspect the invention relates to a pharmaceutical formulation comprising an aqueous solution of a compound according to the present invention, and a buffer, wherein said compound is present in a concentration from 0.1 mg/ml or above, and wherein said formulation has a pH from about 2.0 to about 10.0.

In a another embodiment of the invention the pH of the formulation is selected from the list consisting of 2.0, 2.1, 2.2, 2.3, 2.4, 2.5, 2.6, 2.7, 2.8, 2.9, 3.0, 3.1, 3.2, 3.3, 3.4, 3.5, 3.6, 3.7, 3.8, 3.9, 4.0, 4.1, 4.2, 4.3, 4.4, 4.5, 4.6, 4.7, 4.8, 4.9, 5.0, 5.1, 5.2, 5.3, 5.4, 5.5, 5.6,

5.7, 5.8, 5.9, 6.0, 6.1, 6.2, 6.3, 6.4, 6.5, 6.6, 6.7, 6.8, 6.9, 7.0, 7.1, 7.2, 7.3, 7.4, 7.5, 7.6, 7.7, 7.8, 7.9, 8.0, 8.1, 8.2, 8.3, 8.4, 8.5, 8.6, 8.7, 8.8, 8.9, 9.0, 9.1, 9.2, 9.3, 9.4, 9.5, 9.6, 9.7, 9.8, 9.9, and 10.0.

5 In a further embodiment of the invention the buffer is selected from the group consisting of sodium acetate, sodium carbonate, citrate, glycylglycine, histidine, glycine, lysine, arginin, sodium dihydrogen phosphate, disodium hydrogen phosphate, sodium phosphate, and tris(hydroxymethyl)-aminomethan, bicine, tricine, malic acid, succinate, maleic acid, fumaric acid, tartaric acid, aspartic acid or mixtures thereof. Each one of these specific buffers consti-
10 tutes an alternative embodiment of the invention.

In a further embodiment of the invention the formulation further comprises a pharmaceutically acceptable preservative. In a further embodiment of the invention the preservative is selected from the group consisting of phenol, o-cresol, m-cresol, p-cresol,
15 methyl p-hydroxybenzoate, propyl p-hydroxybenzoate, 2-phenoxyethanol, butyl p-hydroxybenzoate, 2-phenylethanol, benzyl alcohol, chlorobutanol, and thiomerosal, bronopol, benzoic acid, imidurea, chlorohexidine, sodium dehydroacetate, chlorocresol, ethyl p-hydroxybenzoate, benzethonium chloride, chlorphenesine (3p-chlorophenoxypropane-1,2-diol) or mixtures thereof. In a further embodiment of the invention the preservative is present in a
20 concentration from 0.1 mg/ml to 20 mg/ml. In a further embodiment of the invention the preservative is present in a concentration from 0.1 mg/ml to 5 mg/ml. In a further embodiment of the invention the preservative is present in a concentration from 5 mg/ml to 10 mg/ml. In a further embodiment of the invention the preservative is present in a concentration from 10 mg/ml to 20 mg/ml. Each one of these specific preservatives
25 constitutes an alternative embodiment of the invention. The use of a preservative in pharmaceutical compositions is well-known to the skilled person. For convenience reference is made to Remington: *The Science and Practice of Pharmacy*, 19th edition, 1995.

In a further embodiment of the invention the formulation further comprises an isotonic
30 agent. In a further embodiment of the invention the isotonic agent is selected from the group consisting of a salt (e.g. sodium chloride), a sugar or sugar alcohol, an amino acid (e.g. L-glycine, L-histidine, arginine, lysine, isoleucine, aspartic acid, tryptophan, threonine), an alditol (e.g. glycerol (glycerine), 1,2-propanediol (propyleneglycol), 1,3-propanediol, 1,3-butanediol) polyethyleneglycol (e.g. PEG400), or mixtures thereof. Any sugar such as mono-
35 , di-, or polysaccharides, or water-soluble glucans, including for example fructose, glucose,

mannose, sorbose, xylose, maltose, lactose, sucrose, trehalose, dextran, pullulan, dextrin, cyclodextrin, soluble starch, hydroxyethyl starch and carboxymethylcellulose-Na may be used. In one embodiment the sugar additive is sucrose. Sugar alcohol is defined as a C4-C8 hydrocarbon having at least one -OH group and includes, for example, mannitol, sorbitol, inositol, galactitol, dulcitol, xylitol, and arabitol. In one embodiment the sugar alcohol additive is mannitol. The sugars or sugar alcohols mentioned above may be used individually or in combination. There is no fixed limit to the amount used, as long as the sugar or sugar alcohol is soluble in the liquid preparation and does not adversely effect the stabilizing effects achieved using the methods of the invention. In one embodiment, the sugar or sugar alcohol concentration is between about 1 mg/ml and about 150 mg/ml. In a further embodiment of the invention the isotonic agent is present in a concentration from 1 mg/ml to 50 mg/ml. In a further embodiment of the invention the isotonic agent is present in a concentration from 1 mg/ml to 7 mg/ml. In a further embodiment of the invention the isotonic agent is present in a concentration from 8 mg/ml to 24 mg/ml. In a further embodiment of the invention the isotonic agent is present in a concentration from 25 mg/ml to 50 mg/ml. Each one of these specific isotonic agents constitutes an alternative embodiment of the invention. The use of an isotonic agent in pharmaceutical compositions is well-known to the skilled person. For convenience reference is made to Remington: *The Science and Practice of Pharmacy*, 19th edition, 1995.

In a further embodiment of the invention the formulation further comprises a chelating agent. In a further embodiment of the invention the chelating agent is selected from salts of ethylenediaminetetraacetic acid (EDTA), citric acid, and aspartic acid, and mixtures thereof. In a further embodiment of the invention the chelating agent is present in a concentration from 0.1mg/ml to 5mg/ml. In a further embodiment of the invention the chelating agent is present in a concentration from 0.1mg/ml to 2mg/ml. In a further embodiment of the invention the chelating agent is present in a concentration from 2mg/ml to 5mg/ml. Each one of these specific chelating agents constitutes an alternative embodiment of the invention. The use of a chelating agent in pharmaceutical compositions is well-known to the skilled person. For convenience reference is made to Remington: *The Science and Practice of Pharmacy*, 19th edition, 1995.

In a further embodiment of the invention the formulation further comprises a stabiliser. The use of a stabilizer in pharmaceutical compositions is well-known to the skilled per-

son. For convenience reference is made to Remington: *The Science and Practice of Pharmacy*, 19th edition, 1995.

More particularly, compositions of the invention are stabilized liquid pharmaceutical compositions whose therapeutically active components include a polypeptide that possibly exhibits aggregate formation during storage in liquid pharmaceutical formulations. By "aggregate formation" is intended a physical interaction between the polypeptide molecules that results in formation of oligomers, which may remain soluble, or large visible aggregates that precipitate from the solution. By "during storage" is intended a liquid pharmaceutical composition or formulation once prepared, is not immediately administered to a subject. Rather, following preparation, it is packaged for storage, either in a liquid form, in a frozen state, or in a dried form for later reconstitution into a liquid form or other form suitable for administration to a subject. By "dried form" is intended the liquid pharmaceutical composition or formulation is dried either by freeze drying (i.e., lyophilization; see, for example, Williams and Polli (1984) *J. Parenteral Sci. Technol.* 38:48-59), spray drying (see Masters (1991) in *Spray-Drying Handbook* (5th ed; Longman Scientific and Technical, Essex, U.K.), pp. 491-676; Broadhead et al. (1992) *Drug Devel. Ind. Pharm.* 18:1169-1206; and Mumenthaler et al. (1994) *Pharm. Res.* 11:12-20), or air drying (Carpenter and Crowe (1988) *Cryobiology* 25:459-470; and Roser (1991) *Biopharm.* 4:47-53). Aggregate formation by a polypeptide during storage of a liquid pharmaceutical composition can adversely affect biological activity of that polypeptide, resulting in loss of therapeutic efficacy of the pharmaceutical composition. Furthermore, aggregate formation may cause other problems such as blockage of tubing, membranes, or pumps when the polypeptide-containing pharmaceutical composition is administered using an infusion system.

The pharmaceutical compositions of the invention may further comprise an amount of an amino acid base sufficient to decrease aggregate formation by the polypeptide during storage of the composition. By "amino acid base" is intended an amino acid or a combination of amino acids, where any given amino acid is present either in its free base form or in its salt form. Where a combination of amino acids is used, all of the amino acids may be present in their free base forms, all may be present in their salt forms, or some may be present in their free base forms while others are present in their salt forms. In one embodiment, amino acids to use in preparing the compositions of the invention are those carrying a charged side chain, such as arginine, lysine, aspartic acid, and glutamic acid. Any stereoisomer (i.e., L, D, or DL isomer) of a particular amino acid (e.g. glycine, methionine, histidine, imidazole, arginine, lysine, isoleucine, aspartic acid, tryptophan, threonine and mixtures thereof) or combinations of these stereoisomers, may be present in the pharmaceutical

compositions of the invention so long as the particular amino acid is present either in its free base form or its salt form. In one embodiment the L-stereoisomer is used. Compositions of the invention may also be formulated with analogues of these amino acids. By "amino acid analogue" is intended a derivative of the naturally occurring amino acid that brings about the
5 desired effect of decreasing aggregate formation by the polypeptide during storage of the liquid pharmaceutical compositions of the invention. Suitable arginine analogues include, for example, aminoguanidine, ornithine and N-monoethyl L-arginine, suitable methionine analogues include ethionine and buthionine and suitable cysteine analogues include S-methyl-L-cysteine. As with the other amino acids, the amino acid analogues are incorporated into the
10 compositions in either their free base form or their salt form. In a further embodiment of the invention the amino acids or amino acid analogues are used in a concentration, which is sufficient to prevent or delay aggregation of the protein.

In a further embodiment of the invention methionine (or other sulphuric amino acids or amino acid analogous) may be added to inhibit oxidation of methionine residues to
15 methionine sulfoxide when the polypeptide acting as the therapeutic agent is a polypeptide comprising at least one methionine residue susceptible to such oxidation. By "inhibit" is intended minimal accumulation of methionine oxidized species over time. Inhibiting methionine oxidation results in greater retention of the polypeptide in its proper molecular form. Any stereoisomer of methionine (L, D, or DL isomer) or combinations thereof can be used. The
20 amount to be added should be an amount sufficient to inhibit oxidation of the methionine residues such that the amount of methionine sulfoxide is acceptable to regulatory agencies. Typically, this means that the composition contains no more than about 10% to about 30% methionine sulfoxide. Generally, this can be achieved by adding methionine such that the ratio of methionine added to methionine residues ranges from about 1:1 to about 1000:1,
25 such as 10:1 to about 100:1.

In a further embodiment of the invention the formulation further comprises a stabiliser selected from the group of high molecular weight polymers or low molecular compounds. In a further embodiment of the invention the stabilizer is selected from polyethylene glycol (e.g. PEG 3350), polyvinylalcohol (PVA), polyvinylpyrrolidone, carboxy-/hydroxycellulose or
30 derivatives thereof (e.g. HPC, HPC-SL, HPC-L and HPMC), cyclodextrins, sulphur-containing substances as monothioglycerol, thioglycolic acid and 2-methylthioethanol, and different salts (e.g. sodium chloride). Each one of these specific stabilizers constitutes an alternative embodiment of the invention.

The pharmaceutical compositions may also comprise additional stabilizing agents,
35 which further enhance stability of a therapeutically active polypeptide therein. Stabilizing

agents of particular interest to the present invention include, but are not limited to, methionine and EDTA, which protect the polypeptide against methionine oxidation, and a nonionic surfactant, which protects the polypeptide against aggregation associated with freeze-thawing or mechanical shearing.

5

In a further embodiment of the invention the formulation further comprises a surfactant. In a further embodiment of the invention the surfactant is selected from a detergent, ethoxylated castor oil, polyglycolized glycerides, acetylated monoglycerides, sorbitan fatty acid esters, polyoxypropylene-polyoxyethylene block polymers (eg. poloxamers
 10 such as Pluronic® F68, poloxamer 188 and 407, Triton X-100), polyoxyethylene sorbitan fatty acid esters, polyoxyethylene and polyethylene derivatives such as alkylated and alkoxylated derivatives (tweens, e.g. Tween-20, Tween-40, Tween-80 and Brij-35), monoglycerides or ethoxylated derivatives thereof, diglycerides or polyoxyethylene derivatives thereof, alcohols, glycerol, lecitins and phospholipids (eg. phosphatidyl serine,
 15 phosphatidyl choline, phosphatidyl ethanolamine, phosphatidyl inositol, diphosphatidyl glycerol and sphingomyelin), derivatives of phospholipids (eg. dipalmitoyl phosphatidic acid) and lysophospholipids (eg. palmitoyl lysophosphatidyl-L-serine and 1-acyl-sn-glycero-3-phosphate esters of ethanolamine, choline, serine or threonine) and alkyl, alkoxyl (alkyl ester), alkoxy (alkyl ether)- derivatives of lysophosphatidyl and phosphatidylcholines, e.g.
 20 lauroyl and myristoyl derivatives of lysophosphatidylcholine, dipalmitoylphosphatidylcholine, and modifications of the polar head group, that is cholines, ethanolamines, phosphatidic acid, serines, threonines, glycerol, inositol, and the positively charged DODAC, DOTMA, DCP, BISHOP, lysophosphatidylserine and lysophosphatidylthreonine, and glycerophospholipids (eg. cephalins), glyceroglycolipids (eg. galactopyransolide),
 25 sphingoglycolipids (eg. ceramides, gangliosides), dodecylphosphocholine, hen egg lysolecithin, fusidic acid derivatives- (e.g. sodium tauro-dihydrofusidate etc.), long-chain fatty acids and salts thereof C6-C12 (eg. oleic acid and caprylic acid), acylcarnitines and derivatives, N^α-acylated derivatives of lysine, arginine or histidine, or side-chain acylated derivatives of lysine or arginine, N^α-acylated derivatives of dipeptides comprising any
 30 combination of lysine, arginine or histidine and a neutral or acidic amino acid, N^α-acylated derivative of a tripeptide comprising any combination of a neutral amino acid and two charged amino acids, DSS (docusate sodium, CAS registry no [577-11-7]), docusate calcium, CAS registry no [128-49-4]), docusate potassium, CAS registry no [7491-09-0]), SDS (sodium dodecyl sulfate or sodium lauryl sulfate), sodium caprylate, cholic acid or
 35 derivatives thereof, bile acids and salts thereof and glycine or taurine conjugates,

ursodeoxycholic acid, sodium cholate, sodium deoxycholate, sodium taurocholate, sodium glycocholate, N-Hexadecyl-N,N-dimethyl-3-ammonio-1-propanesulfonate, anionic (alkyl-aryl-sulphonates) monovalent surfactants, zwitterionic surfactants (e.g. N-alkyl-N,N-dimethylammonio-1-propanesulfonates, 3-cholamido-1-propyldimethylammonio-1-propanesulfonate, cationic surfactants (quarternary ammonium bases) (e.g. cetyl-trimethylammonium bromide, cetylpyridinium chloride), non-ionic surfactants (eg. Dodecyl β -D-glucopyranoside), poloxamines (eg. Tetronic's), which are tetrafunctional block copolymers derived from sequential addition of propylene oxide and ethylene oxide to ethylenediamine, or the surfactant may be selected from the group of imidazoline derivatives, or mixtures thereof. Each one of these specific surfactants constitutes an alternative embodiment of the invention.

The use of a surfactant in pharmaceutical compositions is well-known to the skilled person. For convenience reference is made to Remington: *The Science and Practice of Pharmacy*, 19th edition, 1995.

15

It is possible that other ingredients may be present in the peptide pharmaceutical formulation of the present invention. Such additional ingredients may include wetting agents, emulsifiers, antioxidants, bulking agents, tonicity modifiers, chelating agents, metal ions, oleaginous vehicles, proteins (e.g., human serum albumin, gelatin or proteins) and a zwitterion (e.g., an amino acid such as betaine, taurine, arginine, glycine, lysine and histidine). Such additional ingredients, of course, should not adversely affect the overall stability of the pharmaceutical formulation of the present invention.

20

Pharmaceutical compositions containing a compound according to the present invention may be administered to a patient in need of such treatment at several sites, for example, at topical sites, for example, skin and mucosal sites, at sites which bypass absorption, for example, administration in an artery, in a vein, in the heart, and at sites which involve absorption, for example, administration in the skin, under the skin, in a muscle or in the abdomen.

25

Administration of pharmaceutical compositions according to the invention may be through several routes of administration, for example, lingual, sublingual, buccal, in the mouth, oral, in the stomach and intestine, nasal, pulmonary, for example, through the bronchioles and alveoli or a combination thereof, epidermal, dermal, transdermal, vaginal, rectal, ocular, for examples through the conjunctiva, uretal, and parenteral to patients in need of such a treatment.

30
35

Compositions of the current invention may be administered in several dosage forms, for example, as solutions, suspensions, emulsions, microemulsions, multiple emulsion, foams, salves, pastes, plasters, ointments, tablets, coated tablets, rinses, capsules, for example, hard gelatine capsules and soft gelatine capsules, suppositories, rectal capsules, drops, gels, sprays, powder, aerosols, inhalants, eye drops, ophthalmic ointments, ophthalmic rinses, vaginal pessaries, vaginal rings, vaginal ointments, injection solution, in situ transforming solutions, for example in situ gelling, in situ setting, in situ precipitating, in situ crystallization, infusion solution, and implants.

Compositions of the invention may further be compounded in, or attached to, for example through covalent, hydrophobic and electrostatic interactions, a drug carrier, drug delivery system and advanced drug delivery system in order to further enhance stability of the compound, increase bioavailability, increase solubility, decrease adverse effects, achieve chronotherapy well known to those skilled in the art, and increase patient compliance or any combination thereof. Examples of carriers, drug delivery systems and advanced drug delivery systems include, but are not limited to, polymers, for example cellulose and derivatives, polysaccharides, for example dextran and derivatives, starch and derivatives, poly(vinyl alcohol), acrylate and methacrylate polymers, polylactic and polyglycolic acid and block copolymers thereof, polyethylene glycols, carrier proteins, for example albumin, gels, for example, thermogelling systems, for example block co-polymeric systems well known to those skilled in the art, micelles, liposomes, microspheres, nanoparticulates, liquid crystals and dispersions thereof, L2 phase and dispersions thereof, well known to those skilled in the art of phase behaviour in lipid-water systems, polymeric micelles, multiple emulsions, self-emulsifying, self-microemulsifying, cyclodextrins and derivatives thereof, and dendrimers.

Compositions of the current invention are useful in the formulation of solids, semisolids, powder and solutions for pulmonary administration of the compound, using, for example a metered dose inhaler, dry powder inhaler and a nebulizer, all being devices well known to those skilled in the art.

Compositions of the current invention are specifically useful in the formulation of controlled, sustained, protracting, retarded, and slow release drug delivery systems. More specifically, but not limited to, compositions are useful in formulation of parenteral controlled release and sustained release systems (both systems leading to a many-fold reduction in number of administrations), well known to those skilled in the art. Even more preferably, are controlled release and sustained release systems administered subcutaneous. Without limiting the scope of the invention, examples of useful controlled release system and composi-

tions are hydrogels, oleaginous gels, liquid crystals, polymeric micelles, microspheres, nanoparticles,

Methods to produce controlled release systems useful for compositions of the current invention include, but are not limited to, crystallization, condensation, co-crystallization, precipitation, co-precipitation, emulsification, dispersion, high pressure homogenization, encapsulation, spray drying, microencapsulation, coacervation, phase separation, solvent evaporation to produce microspheres, extrusion and supercritical fluid processes. General reference is made to Handbook of Pharmaceutical Controlled Release (Wise, D.L., ed. Marcel Dekker, New York, 2000) and Drug and the Pharmaceutical Sciences vol. 99: Protein Formulation and Delivery (MacNally, E.J., ed. Marcel Dekker, New York, 2000).

Parenteral administration may be performed by subcutaneous, intramuscular, intraperitoneal or intravenous injection by means of a syringe, optionally a pen-like syringe. Alternatively, parenteral administration can be performed by means of an infusion pump. A further option is a composition which may be a solution or suspension for the administration of the compound according to the present invention in the form of a nasal or pulmonal spray. As a still further option, the pharmaceutical compositions containing the compound of the invention can also be adapted to transdermal administration, e.g. by needle-free injection or from a patch, optionally an iontophoretic patch, or transmucosal, e.g. buccal, administration.

The term "stabilized formulation" refers to a formulation with increased physical stability, increased chemical stability or increased physical and chemical stability.

The term "physical stability" of the protein formulation as used herein refers to the tendency of the protein to form biologically inactive and/or insoluble aggregates of the protein as a result of exposure of the protein to thermo-mechanical stresses and/or interaction with interfaces and surfaces that are destabilizing, such as hydrophobic surfaces and interfaces. Physical stability of the aqueous protein formulations is evaluated by means of visual inspection and/or turbidity measurements after exposing the formulation filled in suitable containers (e.g. cartridges or vials) to mechanical/physical stress (e.g. agitation) at different temperatures for various time periods. Visual inspection of the formulations is performed in a sharp focused light with a dark background. The turbidity of the formulation is characterized by a visual score ranking the degree of turbidity for instance on a scale from 0 to 3 (a formulation showing no turbidity corresponds to a visual score 0, and a formulation showing visual turbidity in daylight corresponds to visual score 3). A formulation is classified physical unstable with respect to protein aggregation, when it shows visual turbidity in daylight. Alternatively, the turbidity of the formulation can be evaluated by simple turbidity measurements well-known to the skilled person.

Physical stability of the aqueous protein formulations can also be evaluated by using a spectroscopic agent or probe of the conformational status of the protein. The probe is preferably a small molecule that preferentially binds to a non-native conformer of the protein. One example of a small molecular spectroscopic probe of protein structure is Thioflavin T. Thioflavin T is a fluorescent dye that has been widely used for the detection of amyloid fibrils. In the presence of fibrils, and perhaps other protein configurations as well, Thioflavin T gives rise to a new excitation maximum at about 450 nm and enhanced emission at about 482 nm when bound to a fibril protein form. Unbound Thioflavin T is essentially non-fluorescent at the wavelengths.

Other small molecules can be used as probes of the changes in protein structure from native to non-native states. For instance the "hydrophobic patch" probes that bind preferentially to exposed hydrophobic patches of a protein. The hydrophobic patches are generally buried within the tertiary structure of a protein in its native state, but become exposed as a protein begins to unfold or denature. Examples of these small molecular, spectroscopic probes are aromatic, hydrophobic dyes, such as anthracene, acridine, phenanthroline or the like. Other spectroscopic probes are metal-amino acid complexes, such as cobalt metal complexes of hydrophobic amino acids, such as phenylalanine, leucine, isoleucine, methionine, and valine, or the like.

The term "chemical stability" of the protein formulation as used herein refers to chemical covalent changes in the protein structure leading to formation of chemical degradation products with potential less biological potency and/or potential increased immunogenic properties compared to the native protein structure. Various chemical degradation products can be formed depending on the type and nature of the native protein and the environment to which the protein is exposed. Elimination of chemical degradation can most probably not be completely avoided and increasing amounts of chemical degradation products is often seen during storage and use of the protein formulation as well-known by the person skilled in the art. Most proteins are prone to deamidation, a process in which the side chain amide group in glutamyl or asparagyl residues is hydrolysed to form a free carboxylic acid. Other degradations pathways involves formation of high molecular weight transformation products where two or more protein molecules are covalently bound to each other through transamidation and/or disulfide interactions leading to formation of covalently bound dimer, oligomer and polymer degradation products (*Stability of Protein Pharmaceuticals, Ahern. T.J. & Manning M.C., Plenum Press, New York 1992*). Oxidation (of for instance methionine residues) can be mentioned as another variant of chemical degradation. The chemical stability of the protein formulation can be evaluated by measuring the amount of the chemical

degradation products at various time-points after exposure to different environmental conditions (the formation of degradation products can often be accelerated by for instance increasing temperature). The amount of each individual degradation product is often determined by separation of the degradation products depending on molecule size and/or charge using various chromatography techniques (e.g. SEC-HPLC and/or RP-HPLC).

Hence, as outlined above, a "stabilized formulation" refers to a formulation with increased physical stability, increased chemical stability or increased physical and chemical stability. In general, a formulation must be stable during use and storage (in compliance with recommended use and storage conditions) until the expiration date is reached.

In one embodiment of the invention the pharmaceutical formulation comprising the compound according to the present invention is stable for more than 6 weeks of usage and for more than 3 years of storage.

In another embodiment of the invention the pharmaceutical formulation comprising the compound according to the present invention is stable for more than 4 weeks of usage and for more than 3 years of storage.

In a further embodiment of the invention the pharmaceutical formulation comprising the compound according to the present invention is stable for more than 4 weeks of usage and for more than two years of storage.

In an even further embodiment of the invention the pharmaceutical formulation comprising the compound is stable for more than 2 weeks of usage and for more than two years of storage.

Pharmaceutical compositions containing a GLP-1 derivative according to the present invention may be administered parenterally to patients in need of such a treatment. Parenteral administration may be performed by subcutaneous, intramuscular or intravenous injection by means of a syringe, optionally a pen-like syringe. Alternatively, parenteral administration can be performed by means of an infusion pump. A further option is a composition which may be a powder or a liquid for the administration of the GLP-1 derivative in the form of a nasal or pulmonary spray. As a still further option, the GLP-1 derivatives of the invention can also be administered transdermally, e.g. from a patch, optionally a iontophoretic patch, or transmucosally, e.g. buccally.

Thus, the injectable compositions of the GLP-1 derivative of the invention can be prepared using the conventional techniques of the pharmaceutical industry which involves dissolving and mixing the ingredients as appropriate to give the desired end product.

5 According to one procedure, the GLP-1 derivative is dissolved in an amount of water which is somewhat less than the final volume of the composition to be prepared. An isotonic agent, a preservative and a buffer is added as required and the pH value of the solution is adjusted - if necessary - using an acid, *e.g.* hydrochloric acid, or a base, *e.g.* aqueous sodium hydroxide as needed. Finally, the volume of the solution is adjusted with water to give the de-
10 sired concentration of the ingredients.

Further to the above-mentioned components, solutions containing a GLP-1 derivative according to the present invention may also contain a surfactant in order to improve the solubility and/or the stability of the GLP-1 derivative.

15

A composition for nasal administration of certain peptides may, for example, be prepared as described in European Patent No. 272097 (to Novo Nordisk A/S) or in WO 93/18785.

20 According to one preferred embodiment of the present invention, the GLP-1 derivative is provided in the form of a composition suitable for administration by injection. Such a composition can either be an injectable solution ready for use or it can be an amount of a solid composition, *e.g.* a lyophilised product, which has to be dissolved in a solvent before it can be injected. The injectable solution preferably contains not less than about 2 mg/ml, preferably not less than about 5 mg/ml, more preferred not less than about 10 mg/ml of the GLP-1 derivative
25 and, preferably, not more than about 100 mg/ml of the GLP-1 derivative.

30 The GLP-1 derivatives of this invention can be used in the treatment of various diseases. The particular GLP-1 derivative to be used and the optimal dose level for any patient will depend on the disease to be treated and on a variety of factors including the efficacy of the specific peptide derivative employed, the age, body weight, physical activity, and diet of the patient, on a possible combination with other drugs, and on the severity of the case. It is recommended that the dosage of the GLP-1 derivative of this invention be determined for each individual patient by those skilled in the art.

In particular, it is envisaged that the GLP-1 derivative will be useful for the preparation of a medicament with a protracted profile of action for the treatment of non-insulin dependent diabetes mellitus and/or for the treatment of obesity.

5 In another aspect the present invention relates to the use of a compound according to the invention for the preparation of a medicament.

In one embodiment the present invention relates to the use of a compound according to the invention for the preparation of a medicament for the treatment of hyperglycemia, type 2 diabetes, impaired glucose tolerance, type 1 diabetes, obesity, hypertension, syn-
10 drome X, dyslipidemia, β -cell apoptosis, β -cell deficiency, myocardial infarction, inflammatory bowel syndrome, dyspepsia, cognitive disorders, e.g. cognitive enhancing, neuroprotection, atherosclerosis, coronary heart disease and other cardiovascular disorders.

In another embodiment the present invention relates to the use of a compound according to the invention for the preparation of a medicament for the treatment of small bowel
15 syndrome, inflammatory bowel syndrome or Crohns disease.

In another embodiment the present invention relates to the use of a compound according to the invention for the preparation of a medicament for the treatment of hyperglycemia, type 1 diabetes, type 2 diabetes or β -cell deficiency.

20 The treatment with a compound according to the present invention may also be combined with combined with a second or more pharmacologically active substances, e.g. selected from antidiabetic agents, antiobesity agents, appetite regulating agents, antihypertensive agents, agents for the treatment and/or prevention of complications resulting from or associated with diabetes and agents for the treatment and/or prevention of complications
25 and disorders resulting from or associated with obesity. In the present context the expression "antidiabetic agent" includes compounds for the treatment and/or prophylaxis of insulin resistance and diseases wherein insulin resistance is the pathophysiological mechanism.

Examples of these pharmacologically active substances are : Insulin, GLP-1 agonists, sulphonylureas (e.g. tolbutamide, glibenclamide, glipizide and gliclazide), biguanides
30 e.g. metformin, meglitinides, glucosidase inhibitors (e.g. acarbose), glucagon antagonists, DPP-IV (dipeptidyl peptidase-IV) inhibitors, inhibitors of hepatic enzymes involved in stimulation of gluconeogenesis and/or glycogenolysis, glucose uptake modulators, thiazolidinediones such as troglitazone and ciglitazone, compounds modifying the lipid metabolism
such as antihyperlipidemic agents as HMG CoA inhibitors (statins), compounds lowering
35 food intake, RXR agonists and agents acting on the ATP-dependent potassium channel of

the β -cells, e.g. glibenclamide, glipizide, gliclazide and repaglinide; Cholestyramine, colestipol, clofibrate, gemfibrozil, lovastatin, pravastatin, simvastatin, probucol, dextrothyroxine, neteglinide, repaglinide; β -blockers such as alprenolol, atenolol, timolol, pindolol, propranolol and metoprolol, ACE (angiotensin converting enzyme) inhibitors such as benazepril, captopril, enalapril, fosinopril, lisinopril, alatriopril, quinapril and ramipril, calcium channel blockers such as nifedipine, felodipine, nicardipine, isradipine, nimodipine, diltiazem and verapamil, and α -blockers such as doxazosin, urapidil, prazosin and terazosin; CART (cocaine amphetamine regulated transcript) agonists, NPY (neuropeptide Y) antagonists, MC4 (melanocortin 4) agonists, orexin antagonists, TNF (tumor necrosis factor) agonists, CRF (corticotropin releasing factor) agonists, CRF BP (corticotropin releasing factor binding protein) antagonists, urocortin agonists, $\beta 3$ agonists, MSH (melanocyte-stimulating hormone) agonists, MCH (melanocyte-concentrating hormone) antagonists, CCK (cholecystokinin) agonists, serotonin re-uptake inhibitors, serotonin and noradrenaline re-uptake inhibitors, mixed serotonin and noradrenergic compounds, 5HT (serotonin) agonists, bombesin agonists, galanin antagonists, growth hormone, growth hormone releasing compounds, TRH (thyrotropin releasing hormone) agonists, UCP 2 or 3 (uncoupling protein 2 or 3) modulators, leptin agonists, DA agonists (bromocriptin, doprexin), lipase/amylase inhibitors, RXR (retinoid X receptor) modulators, TR β agonists; histamine H3 antagonists.

It should be understood that any suitable combination of the compounds according to the invention with one or more of the above-mentioned compounds and optionally one or more further pharmacologically active substances are considered to be within the scope of the present invention.

The present invention is further illustrated by the following examples which, however, are not to be construed as limiting the scope of protection. The features disclosed in the foregoing description and in the following examples may, both separately and in any combination thereof, be material for realising the invention in diverse forms thereof.

EXAMPLES

The following acronyms for commercially available chemicals are used:

	DMF	:	N,N-Dimethylformamide.
	DCC	:	N,N-Dicyclohexylcarbodiimide
	NMP	:	N-Methyl-2-pyrrolidone.
	EDPA	:	N-Ethyl-N,N-diisopropylamine.
5	EGTA	:	Ethylene glycol-bis(β -aminoethyl ether)-N,N,N',N'-tetraacetic acid.
	GTP		Guanosine 5'-triphosphate.
	TFA	:	Trifluoroacetic acid.
	THF	:	Tetrahydrofuran
	H-Glu(OH)-OBu ^t :		L-Glutamic acid α -tert-butyl ester
10	Cap-ONSu:		Octanoic acid 2,5-dioxopyrrolidin-1-yl ester
	Lau-ONSu:		Dodecanoic acid 2,5-dioxopyrrolidin-1-yl ester
	Myr-ONSu:		Tetradecanoic acid 2,5-dioxopyrrolidin-1-yl ester.
	Pal-ONSu:		Hexadecanoic acid 2,5-dioxopyrrolidin-1-yl ester.
	Ste-ONSu		Octadecanoic acid 2,5-dioxopyrrolidin-1-yl ester.

15

Abbreviations:

PDMS: Plasma Desorption Mass Spectrometry

MALDI-MS: Matrix Assisted Laser Desorption/Ionisation Mass Spectrometry

HPLC: High Performance Liquid Chromatography

20 amu: atomic mass units

Lit-Glu(ONSu)-OBu^t: N ^{α} -Lithochoyl-L-glutamic acid α -t-butyl ester γ -2,5-dioxopyrrolidin-1-yl esterCap-Glu(ONSu)-OBu^t: N ^{α} -Octanoyl-L-glutamic acid α -t-butyl ester γ -2,5-dioxopyrrolidin-1-yl ester25 Cac-Glu(ONSu)-OBu^t: N ^{α} -Decanoyl-L-glutamic acid α -t-butyl ester γ -2,5-dioxopyrrolidin-1-yl esterLau-Glu(ONSu)-OBu^t: N ^{α} -Dodecanoyl-L-glutamic acid α -t-butyl ester γ -2,5-dioxopyrrolidin-1-yl ester30 Myr-Glu(ONSu)-OBu^t: N ^{α} -Tetradecanoyl-L-glutamic acid α -t-butyl ester γ -2,5-dioxopyrrolidin-1-yl esterPal-Glu(ONSu)-OBu^t: N ^{α} -Hexadecanoyl-(L)-glutamic acid α -t-butyl- γ -2,5-dioxopyrrolidin-1-yl diester.Ste-Glu(ONSu)-OBu^t: N ^{α} -Octadecanoyl-(L)-glutamic acid α -t-butyl- γ -2,5-dioxopyrrolidin-1-yl diester35 Lau- β -Ala-ONSu: N ^{β} -Dodecanoyl- β -alanine 2,5-dioxopyrrolidin-1-yl ester

- Pal- β -Ala-ONSu: N ^{β} -Hexadecanoyl- β -alanine 2,5-dioxopyrrolidin-1-yl ester
 Lau-GABA-ONSu: N ^{γ} -Dodecanoyl- γ -aminobutyric acid 2,5-dioxopyrrolidin-1-yl ester
 Myr-GABA-ONSu: N ^{γ} -Tetradecanoyl- γ -aminobutyric acid 2,5-dioxopyrrolidin-1-yl ester
 Pal-GABA-ONSu: N ^{γ} -Hexadecanoyl- γ -aminobutyric acid 2,5-dioxopyrrolidin-1-yl ester
 5 Ste-GABA-ONSu: N ^{γ} -Octadecanoyl- γ -aminobutyric acid 2,5-dioxopyrrolidin-1-yl ester
 Pal-Isonip-ONSu: N-Hexadecanoyl-piperidine-4-carboxylic acid 2,5-dioxopyrrolidin-1-yl ester
 Pal-Glu(OBu^t)-ONSu: N ^{α} -Hexadecanoyl-L-glutamic acid α -2,5-dioxopyrrolidin-1-yl ester
 γ -t-butyl ester
 10 HOOC-(CH₂)₈-COONSu: ω -Carboxyheptanoic acid 2,5-dioxopyrrolidin-1-yl ester.
 HOOC-(CH₂)₁₀-COONSu: ω -Carboxyundecanoic acid 2,5-dioxopyrrolidin-1-yl ester.
 HOOC-(CH₂)₁₂-COONSu: ω -Carboxytridecanoic acid 2,5-dioxopyrrolidin-1-yl ester.
 HOOC-(CH₂)₁₄-COONSu: ω -Carboxypentadecanoic acid 2,5-dioxopyrrolidin-1-yl ester.
 15 HOOC-(CH₂)₁₆-COONSu: ω -Carboxyheptadecanoic acid 2,5-dioxopyrrolidin-1-yl ester.
 HOOC-(CH₂)₁₈-COONSu: ω -Carboxynonadecanoic acid 2,5-dioxopyrrolidin-1-yl ester.

20 Analytical

Plasma Desorption Mass Spectrometry

Sample preparation:

- 25 The sample is dissolved in 0.1 % TFA/EtOH (1:1) at a concentration of 1 μ g/ μ l. The sample solution (5-10 μ l) is placed on a nitrocellulose target (Bio-ion AB, Uppsala, Sweden) and allowed to adsorb to the target surface for 2 minutes. The target is subsequently rinsed with 2x25 μ l 0.1 % TFA and spin-dried. Finally, the nitrocellulose target is placed in a target carousel and introduced into the mass spectrometer.

30

MS analysis:

- PDMS analysis was carried out using a Bio-ion 20 time-of flight instrument (Bio-ion Nordic AB, Uppsala, Sweden). An acceleration voltage of 15 kV was applied and molecular ions
 35 formed by bombardment of the nitrocellulose surface with 252-Cf fission fragments were accelerated towards a stop detector. The resulting time-of-flight spectrum was calibrated into a

true mass spectrum using the H^+ and NO^+ ions at m/z 1 and 30, respectively. Mass spectra were generally accumulated for 1.0×10^6 fission events corresponding to 15-20 minutes. Resulting assigned masses all correspond to isotopically averaged molecular masses. The accuracy of mass assignment is generally better than 0.1 %.

5

MALDI-MS

10 MALDI-TOF MS analysis was carried out using a Voyager RP instrument (PerSeptive Biosystems Inc., Framingham, MA) equipped with delayed extraction and operated in linear mode. Alpha-cyano-4-hydroxy-cinnamic acid was used as matrix, and mass assignments were based on external calibration.

Synthetic methods

15 The peptide was synthesized on Fmoc protected Rink amide resin (Novabiochem) or chlorotriyl resin using Fmoc strategy on an Applied Biosystems 433A peptide synthesizer in 0.25 mmol scale using the manufacturer supplied FastMoc UV protocols which employ HBTU (2-(1H-Benzotriazol-1-yl)-1,1,3,3 tetramethyluronium hexafluorophosphate) mediated couplings in NMP (N-methyl pyrrolidone) and UV monitoring of the deprotection of the Fmoc
20 protection group. The protected amino acid derivatives used were standard Fmoc-amino acids (Anaspec) supplied in preweighed cartridges suitable for the ABI433A synthesizer with the exception of unnatural amino acids such as Fmoc-Aib-OH (Fmoc-aminoisobutyric acid).

25 The attachment of sidechains and linkers to specific lysine residues on the crude resin bound protected peptide was carried out in a specific position by incorporation of Fmoc-Lys(Dde)-OH during automated synthesis.

Procedure for removal of Fmoc-protection:

30 Procedure for attachment of sidechains to Lysine residues

Procedure for removal of Dde-protection. Afterward the resin was placed in a manual shaker/filtration apparatus and treated with 2% hydrazine in DMF to remove the DDE group. Then sidechains were attached manually using HOBt/EDAC couplings in NMP and standard
35 Fmoc-deprotection using 20% piperidine in DMF.

Procedure for cleaving of peptide of resin:

5 The peptide was cleaved from the resin by stirring for 240 min at room temperature with a mixture of trifluoroacetic acid, water and triisopropylsilane (95:2.5:2.5). The cleavage mixture was filtered and the filtrate was concentrated to an oil by a stream of nitrogen. The crude peptide was precipitated from this oil with 45 ml diethyl ether and washed 3 times with 45 ml diethyl ether.

10 **Purification:**

The crude peptide was purified by semipreparative HPLC on a 20 mm x 250 mm column packed with 7 μ C-18 silica. The column was equilibrated with 21% CH₃CN in 0.05M (NH₄)₂SO₄, which was adjusted to pH 2.5 with concentrated H₂SO₄. After drying the crude peptide was dissolved in 5 ml 70% CH₃CN / 0.1% TFA in H₂O and diluted to 50 ml with H₂O.
15 20 ml of this solution was diluted to 90 ml and injected on the column which then was eluted with a gradient of 21% - 31% CH₃CN in 0.05M (NH₄)₂SO₄, pH 2.5 at 10 ml/min during 47 min at 40 °C. The peptide containing fractions were collected and diluted with 3 volumes of H₂O and passed through a Sep-Pak® C18 cartridge (Waters part. #:51910) which has been equilibrated with 0.1% TFA. It was then eluted with 70% CH₃CN containing 0.1% TFA and
20 the purified peptide was isolated by lyophilisation after dilution of the eluate with water. The final product obtained was characterised by analytical RP-HPLC (retention time) and by LCMS

The RP-HPLC analysis was performed using UV detection at 214 nm and a Vydac 218TP54 4.6mm x 250mm 5 μ C-18 silica column (The Separations Group, Hesperia, USA) which was
25 eluted at 1 ml/min at 42 °C. Two different elution conditions were used:

A1: Equilibration of the column with 5% CH₃CN in a buffer consisting of 0.1M (NH₄)₂SO₄, which was adjusted to pH 2.5 with concentrated H₂SO₄ and elution by a gradient of 5% to 60% CH₃CN in the same buffer during 50 min.


B1: Equilibration of the column with 5% CH₃CN / 0.1% TFA / H₂O and elution by a gradient of 5% CH₃CN / 0.1% TFA / H₂O to 60% CH₃CN / 0.1% TFA / H₂O during 50 min.
30

B6:

LCMS :

35 **Example 1**

N^{637} -(2-(2-(2-(dodecylamino)ethoxy)ethoxy)acetyl)-[Aib^{8,22,35}] GLP-1 H-(7-37)-NH₂



Prepared as in "Synthetic methods".

HPLC: (method B6): RT=32.8 min (98%)


5 HPLC: (method A1): RT=43.6 min

LCMS: m/z = 765.0 (M+H)⁵⁺, 957.0 (M+H)⁴⁺, 1275.0 (M+H)³⁺ Calculated (M+H)⁺ = 3825.0

Example 2

N^{637} -(2-(2-(2-(17-sulphohexadecanoylamino)ethoxy)ethoxy)acetyl)-[Aib^{8,22,35},Lys37] GLP-1

10 H-(7-37)-NH₂



Prepared as in "Synthetic methods".


HPLC: (method A1): RT=45.5 min

15 LCMS: m/z = 792.9 (M+H)⁵⁺, 990.9 (M+H)⁴⁺, 1320.9 (M+H)³⁺ Calculated (M+H)⁺ = 3959.9

Example 3

N^{637} -(2-(2-(2-(15-carboxyhexadecanoylamino)ethoxy)ethoxy)acetyl)-[Aib^{8,22,35},Lys³⁷] GLP-1

20 H-(7-37)-NH₂



Prepared as in "Synthetic methods".

HPLC: (method B1): RT=43.8 min (92%)


HPLC: (method A1): RT=42.0 min

LCMS: m/z = 978.3 $(M+H)^{4+}$, 1303.8 $(M+H)^{3+}$ Calculated $(M+H)^+ = 3909.6$

5

Example 4

$N^{\epsilon 37}$ -(2-(2-(2-(17-carboxyheptadecanoylamino)ethoxy)ethoxy)acetyl)[Aib^{8,22,35},Lys³⁷]GLP-1 H
(7-37) -NH₂



10 Prepared as in "Synthetic methods".


HPLC: (method B1): RT=46.4 min (100%)

HPLC: (method A1): RT=44.4 min

LCMS: m/z = 985.5 $(M+H)^{4+}$, 1313.4 $(M+H)^{3+}$ Calculated $(M+H)^+ = 3937.6$

15 Example 5

$N^{\epsilon 37}$ -(2-(2-(2-(19-carboxynonadecanoylamino)ethoxy)ethoxy)acetyl)[Aib^{8,22,35},Lys³⁷]GLP-1 H
(7-37) -NH₂



Prepared as in "Synthetic methods".


20 HPLC: (method B1): RT=49.5 min (100%)

HPLC: (method A1): RT=47.1 min

LCMS: m/z = 992.5 $(M+H)^{4+}$, 1322.6 $(M+H)^{3+}$ Calculated $(M+H)^+ = 3965.7$

Example 6

25 $N^{\epsilon 38}$ -(4-(hexadecanoylamino)-4(S)-carboxybutyryl)-[Aib^{8,22,35},Arg^{28,34}] GLP-1 H-(7-37) Lys
NH₂



Prepared as in "Synthetic methods".


HPLC: (method B6): RT=36.28min 49.5 min (100%)

LCMS: m/z = 995 ($M+H$)⁴⁺, 1326 ($M+H$)³⁺ Calculated ($M+H$)⁺ = 3977.6

5

Example 7

N^{ε38}-(2-(2-(2-(hexadecanoylamino)ethoxy)ethoxy)acetyl)-[Aib^{8,22,35},Arg^{26,34}] GLP-1 H-(7-37)Lys NH₂



10


Prepared as in "Synthetic methods".

HPLC: (method B6): RT=37.1min (100%)

LCMS: m/z = 999 ($M+H$)⁴⁺, 1332 ($M+H$)³⁺ Calculated ($M+H$)⁺ = 3993.7

15 Example 8

N^{ε37}(2-[2-(2,6-(S)-Bis-{2-[2-(2-(dodecanoylamino)ethoxy)ethoxy]acetyl amino}hexanoylamino)ethoxy]ethoxy)) acetyl-[Aib^{8,22,35}]GLP-1 H-(7-37)-NH₂



20


Prepared as in "Synthetic methods".

HPLC: (method B6): RT=38.2 min (100%)

LCMS: m/z = 1106.7 (M+H)⁴⁺, 1475.3 (M+H)³⁺ Calculated (M+H)⁺ = 4433.0

5 Example 9

N^{ε37}-(2-[2-(2,6-(S)-Bis-{2-[2-(2-(tetradecanoylamino)ethoxy)ethoxy]acetyl amino}hexanoylamino)ethoxy]ethoxy)) acetyl-[Aib^{8,22,35}]GLP-1 H-(7-37)-NH₂



10


Prepared as in "Synthetic methods".

HPLC: (method B6): RT=42.9 min (90%)

LCMS: m/z = 1120.9 (M+H)⁴⁺, 1494.2 (M+H)³⁺ Calculated (M+H)⁺ = 4480.4

15 Example 10

N^{ε38}-epsilon38-(2-(2-(2-(4-(hexadecanoylamino)-4(S)-carboxybutyrylamino)ethoxy)ethoxy)acetyl)-[Aib^{8,22,35},Arg^{28,34}] GLP-1 H-(7-37) Lys-OH




20 Prepared as in "Synthetic methods".

HPLC: (method B6): RT=36.0 min (100%)

LCMS: m/z = 1032.0 (M+H)⁴⁺, 1374.0 (M+H)³⁺ Calculated (M+H)⁺ = 4122.8

Example 11

N^{ε38}-(2-(2-[4-[4-(4-Amino-9,10-dioxo-3-sulfo-9,10-dihydro-anthracen-1-ylamino)-2-sulfo-phenylamino]-6-(2-sulfo-phenylamino)-[1,3,5]triazin-2-ylamino]-ethoxy)-ethoxy)-acetyl)-[Aib^{8,22,35}] GLP-1 H (7-37)Lys-NH₂



5

Prepared by loading DdeLys(Fmoc)-OH onto Rink resin. The resin was then treated with piperidine as in "Synthetic methods" to remove Fmoc selectively. 2-(2-(2-(Fmoc-amino)ethoxy)ethoxy)acetic acid was coupled onto the epsilon amingroup of lysine and Fmoc was removed. DMSO and Cibacron Blue 3GA (17 equivalents) (Sigma C-9534) was added and the mixture was heated at 60 °C for 15 hours, washed with water (3 times), methanol (2 times), THF (2 times) and diethyl ether (2 times). The Dde protecting group was removed and the remaining amino acids were added as in "Synthetic methods"

10

HPLC: (method A1): RT=38.1 min (92%)


15

LCMS: m/z = 1110.4 (M+H)⁴⁺, 1436.4 (M+H)³⁺ Calculated (M+H)⁺ = 4435.9

Example 12

N^{ε38}-({2-[2-(2-[2-(2-[2-(2-[15-carboxypentadecanoylamino)-ethoxy]ethoxy)acetyl]amino)ethoxy]ethoxy)acetyl]amino)ethoxy]ethoxy)acetyl)-[Aib^{8,22,35}] GLP-1 H (7-37)Lys- NH₂

20



HPLC: (method A1): RT=41.2 min (93%)


HPLC: (method B6): RT=30.7 min

LCMS: m/z = 1069.1 ($M+H$)⁴⁺, 1424.6 ($M+H$)³⁺ Calculated ($M+H$)⁺ = 4271

5

Example 13

N^{ε38}-([2-(2-{3-[2,5-dioxo-3-(15-carboxypentadecylsulfanyl)-pyrrolidin-1-yl]-propionylamino}ethoxy)ethoxy)acetyl]-[D-Ala⁸,Lys³⁷]-GLP-1-[7-37]NH₂




10

HPLC: (method A1): RT=45.2 min (100%)

LCMS: m/z = 1004.0 ($M+H$)⁴⁺, 1338.2 ($M+H$)³⁺ Calculated ($M+H$)⁺ = 4010.7

Example 14

15 N^{ε38}-(2-(2-(2-(11-(oxalylamino)undecanoylamino)ethoxy)ethoxy)acetyl-)) [Aib^{8,22,35}, Ala³⁷,Lys³⁸] GLP-1 H-(7-37)Lys-NH₂




HPLC (method A1): RT=37.9 min (100%)

HPLC (method B1): RT=39.5 min (100%)

20. LCMS: m/z = 993.3 ($M+H$)⁴⁺, 1323.9 ($M+H$)³⁺ Calculated ($M+H$)⁺ = 3967.6

Example 15

N⁶³⁸}{(2-[2-(2-[2-(2-(15-carboxy-pentadecanoylamino)-ethoxy]ethoxy)acetylamin)ethoxy]ethoxy}acetyl)[Aib^{8,22,35},Ala³⁷]-GLP-1[7-37]Lys NH₂



HPLC (method A1): RT=41.1 min (98%)

HPLC (method B6): RT=31.1 min

LCMS: $m/z = 1351.8$ $(M+H)^{3+}$ Calculated $(M+H)^+ = 4052.0$

5

Example 18

Example 18
N^{ε38}-2-(2-(2-(octadecanoylamino)ethoxy)ethoxy)acetyl [Aib⁸, Arg^{26,34}, Glu^{22,23,30}]GLP-1 H(7-

37) Lys-NH₂

10



HPLC (method B6): RT=39.3 min (89.9%)

LCMS: $m/z = 1366.6 (M+H)^{3+}$ Calculated $(M+H)^+ = 4095.6$

15

Example 19

Example 19
 $N^{\epsilon 38}$ -2-(2-(2-(eicosanoylamino)ethoxy)ethoxy)acetyl [Aib⁸, Arg^{28,34}, Glu^{22,23,30}]GLP-1 H(7-

37) Lys-NH₂




20

HPLC (method B6): RT=42.6 min (88.5%)

LCMS: $m/z = 1375.7$ ($M+H$)³⁺ Calculated ($M+H$)⁺ = 4123.7


Example 20

- 5 Gly8,Arg26,34,36,Lys38 (N-epsilon({2-[2-(2-[2-(4-Carboxy-4-octadecanoylamino-butrylamino)ethoxy]ethoxy)acetylamin)ethoxy]ehoxy}-acetic acid))GLP-1 (7-38)



HPLC MS (incl methode): Rf = , mw =


10 Example 21



HPLC MS (incl methode): Rf = , mw =

Example 22

- 15 Aib8,Lys38-(N-epsilon-2-(2-(2-(gamma-glutamyl(N-alfa-hexadecanoyl))aminoethoxy)ethoxy)acetyl)-GLP-1 (7-38)




HPLC MS (incl methode): Rf = , mw =


20

Example 23

56

HPLC MS (incl methode): R_f = , mw =


Example 24



5

HPLC MS (incl methode): R_f = , mw =


Example 25

10 HPLC MS (incl methode): R_f = , mw =

Example 26

Aib8,Lys38-(N-epsilon-2-(2-(2-(2-(2-(gamma-glutamyl(N-alfa-hexadecanoyl))aminoethoxy)ethoxy)acetyl)

15 aminoethoxy)ethoxy)acetyl-GLP-1 (7-38)

HPLC MS (incl methode): R_f = , mw =

Example 27

20

HPLC MS (incl methode): Rf = , mw =


Example 28

5

HPLC MS (incl methode): Rf = , mw =

Example 29

10 [Aib8,22,35,Lys(C12oyl-Aminoethoxy-ethoxyAcetyl)-37] GLP-1 H-(7-37)-NH2




HPLC: (method B6): RT=32,8 min (98%)

LC-MS: m/z = 765,7 (M+H)⁵⁺, 957,0 (M+H)⁴⁺, 1275,7 (M+H)³⁺ = 3822,9

15

Example 30

Aib8,22,35,Lys(N-epsilon-C14oyl-aminoethoxyethoxyacetyl)-37] GLP-1 -(7-37)-NH2




20

HPLC: (method B6): RT= 34,6 min (96%)

LC-MS: m/z = 771,4 (M+H)⁵⁺, 964,1(M+H)⁴⁺, 1284,9(M+H)³⁺ = 3851,5

Example 31

[Aib8,22,35,Lys(C16oyl-Aminoethoxy-ethoxyAcetyl-)-37] GLP-1 H-(7-37)-NH₂




5

HPLC: (method B6): RT= 36,8 min (99%)

LC-MS: m/z = 970,7(M+H)⁴⁺, 1294,3(M+H)³⁺ = 3879,6

Example 32

10 [Aib8,22,35,Lys(C18oyl-Aminoethoxy-ethoxyAcetyl-)-37] GLP-1 H-(7-37)-NH₂




HPLC: (method B6): RT= 39,4 min (100%)

LC-MS: m/z = 977,9 (M+H)⁴⁺, 1303,7(M+H)³⁺ = 3907,6

15

Example 33

[Aib8,22,35,Lys(C20oyl-Aminoethoxy-ethoxyAcetyl-)-37] GLP-1 H-(7-37)-NH₂



HPLC: (method B6): RT= 42,7min (100%)

LC-MS: m/z = 984,8(M+H)⁴⁺, 1312,8(M+H)³⁺ = 3935,7

5

BIOLOGICAL FINDINGS

Protraction of GLP-1 derivatives after s.c. administration

The protraction of a number GLP-1 derivatives of the invention was determined by monitoring the concentration thereof in plasma after sc administration to healthy pigs, using the method described below. For comparison also the concentration in plasma of GLP-1(7-37) after sc. administration was followed. The protraction of other GLP-1 derivatives of the invention can be determined in the same way.

Pigs (50% Duroc, 25% Yorkshire, 25% Danish Landrace, app 40 kg) were fasted from the beginning of the experiment. To each pig 0.5 nmol of test compound per kg body weight was administered in a 50 μ M isotonic solution (5 mM phosphate, pH 7.4, 0.02% Tween[®]-20 (Merck), 45 mg/ml mannitol (pyrogen free, Novo Nordisk). Blood samples were drawn from a catheter in vena jugularis. 5 ml of the blood samples were poured into chilled glasses containing 175 μ l of the following solution: 0.18 M EDTA, 1500 KIE/ml aprotinin (Novo Nordisk) and 3% bacitracin (Sigma), pH 7.4. Within 30 min, the samples were centrifuged for 10 min at 5-6000*g. Temperature was kept at 4°C. The supernatant was pipetted into different glasses and kept at minus 20°C until use.

The plasma concentrations of the peptides were determined by RIA using a monoclonal antibody specific for the N-terminal region of GLP-1(7-37). The cross reactivities were less than

1% with GLP-1(1-37) and GLP-1(8-36)amide and < 0.1% with GLP-1(9-37), GLP-1(10-36)amide and GLP-1(11-36)amide. The entire procedure was carried out at 4°C.

5 The assay was carried out as follows: 100 µl plasma was mixed with 271 µl 96% ethanol, mixed using a vortex mixer and centrifuged at 2600*g for 30 min. The supernatant was decanted into Minisorp tubes and evaporated completely (Savant Speedvac AS290). The evaporation residue was reconstituted in the assay buffer consisting of 80 mM $\text{NaH}_2\text{PO}_4/\text{Na}_2\text{HPO}_4$, 0.1 % HSA (Orpha 20/21, Behring), 10 mM EDTA, 0.6 mM thiomersal (Sigma), pH 7.5. Samples were reconstituted in volumes suitable for their expected concentrations, and were allowed to reconstitute for 30 min. To 300 µl sample, 100 µl antibody solution in dilution buffer containing 40 mM $\text{NaH}_2\text{PO}_4/\text{Na}_2\text{HPO}_4$, 0.1 % HSA, 0.6 mM thiomersal, pH 7.5, was added. A non-specific sample was prepared by mixing 300 µl buffer with 100 µl dilution buffer. Individual standards were prepared from freeze dried stocks, dissolved in 300 µl assay buffer. All samples were pre-incubated in Minisorp tubes with antibody as described above for 72 h. 200 µl tracer in dilution buffer containing 6-7000 CPM was added, samples were mixed and incubated for 48 h. 1.5 ml of a suspension of 200 ml per litre of heparin-stabilised bovine plasma and 18 g per litre of activated carbon (Merck) in 40 mM $\text{NaH}_2\text{PO}_4/\text{Na}_2\text{HPO}_4$, 0.6 mM thiomersal, pH 7.5, was added to each tube. Before use, the suspension was mixed and allowed to stand for 2 h at 4°C. All samples were incubated for 1 h at 4°C and then centrifuged at 3400*g for 25 min. Immediately after the centrifugation, the supernatant was decanted and counted in a γ-counter. The concentration in the samples was calculated from individual standard curves. Plasma concentrations were found, calculated as % of the maximum concentration for the individual compounds (n=2). The GLP-1 derivatives of the invention have a protracted profile of action relative to GLP-1(7-37) and are much more persistent in plasma than GLP-1(7-37). The time at which the peak concentration in plasma is achieved varies within wide limits, depending on the particular GLP-1 derivative selected.

30 **Stimulation of cAMP formation in a cell line expressing the cloned human GLP-1 receptor**

In order to demonstrate efficacy of the GLP-1 derivatives, their ability to stimulate formation of cAMP in a cell line expressing the cloned human GLP-1 receptor was tested. An EC_{50} was calculated from the dose-response curve.

Baby hamster kidney (BHK) cells expressing the human pancreatic GLP-1 receptor were used (Knudsen and Pridal, 1996, Eur. J. Pharm. 318, 429-435). Plasma membranes were prepared (Adelhorst *et al*, 1994, J. Biol. Chem. 269, 6275) by homogenisation in buffer (10 mmol/l Tris-HCl and 30 mmol/l NaCl pH 7.4, containing, in addition, 1 mmol/l dithiothreitol, 5 mg/l leupeptin (Sigma, St. Louis, MO, USA), 5 mg/l pepstatin (Sigma, St. Louis, MO, USA), 100 mg/l bacitracin (Sigma, St. Louis, MO, USA), and 16 mg/l aprotinin (Novo Nordisk A/S, Bagsvaerd, Denmark)). The homogenate was centrifuged on top of a layer of 41 w/v% sucrose. The white band between the two layers was diluted in buffer and centrifuged. Plasma membranes were stored at -80°C until used.

The assay was carried out in 96-well microtiter plates in a total volume of 140 µl. The buffer used was 50 mmol/l Tris-HCl, pH 7.4 with the addition of 1 mmol/l EGTA, 1.5 mmol/l MgSO₄, 1.7 mmol/l ATP, 20 mM GTP, 2 mmol/l 3-isobutyl-1-methylxanthine, 0.01 % Tween-20 and 0.1 % human serum albumin (Reinst, Behringwerke AG, Marburg, Germany). Compounds to be tested for agonist activity were dissolved and diluted in buffer, added to the membrane preparation and the mixture was incubated for 2 h at 37°C. The reaction was stopped by the addition of 25 µl of 0.05 mol/l HCl. Samples were diluted 10 fold before analysis for cAMP by a scintillation proximity assay (RPA 538, Amersham, UK).

CLAIMS

1. A compound which comprises a therapeutic polypeptide linked to an albumin binding residue
 5 via a hydrophilic spacer.

2. A compound which comprises a therapeutic polypeptide linked to an albumin binding residue
 via a hydrophilic spacer $-(CH_2)_l D[(CH_2)_n E]_m (CH_2)_p Q_q-$, wherein

l, m and n independently are 1-20 and p is 0-10,

10 Q is $-Z-(CH_2)_l D[(CH_2)_n G]_m (CH_2)_p-$,

q is 0 or 1,

each D, E, and G independently are selected from $-O-$, $-NR^3-$, $-N(COR^4)-$, $-PR^5(O)-$,

and $-P(OR^6)(O)-$, wherein R^3 , R^4 , R^5 , and R^6 independently represent hydrogen or
 C_{1-6} -alkyl,

15 Z is selected from $-C(O)NH-$, $-C(O)NHCH_2-$, $-OC(O)NH-$, $-C(O)NHCH_2CH_2-$,
 $-C(O)CH_2-$, $-C(O)CH=CH-$, $-(CH_2)_s-$, $-C(O)-$, $-C(O)O-$ or $-NHC(O)-$, wherein s is 0 or

1

or a pharmaceutically acceptable salt or prodrug thereof.

20 3. A compound according to claim 2, which has the formula (I):



wherein

A is an albumin binding residue,

B is a hydrophilic spacer being $-(CH_2)_l D[(CH_2)_n E]_m (CH_2)_p Q_q-$, wherein

25 l, m and n independently are 1-20 and p is 0-10,

Q is $-Z-(CH_2)_l D[(CH_2)_n G]_m (CH_2)_p-$,

q is 0 or 1,

each D, E, and G independently are selected from $-O-$, $-NR^3-$, $-N(COR^4)-$, $-PR^5(O)-$,

and $-P(OR^6)(O)-$, wherein R^3 , R^4 , R^5 , and R^6 independently represent hydrogen or

30 C_{1-6} -alkyl,

Z is selected from $-C(O)NH-$, $-C(O)NHCH_2-$, $-OC(O)NH-$, $-C(O)NHCH_2CH_2-$,

$-C(O)CH_2-$, $-C(O)CH=CH-$, $-(CH_2)_s-$, $-C(O)-$, $-C(O)O-$ or $-NHC(O)-$, wherein s is 0 or

1,

Y is a chemical group linking B and the therapeutic agent, and

35 W is a chemical group linking A and B.

4. A compound according to claim 2, which has the formula (II)



wherein

5 A and A' are albumin binding residues,

B and B' are hydrophilic spacers independently selected from $-(CH_2)_lD[(CH_2)_nE]_m(CH_2)_p-Q_q-$,

wherein

l, m and n independently are 1-20 and p is 0-10,

Q is $-Z-(CH_2)_lD[(CH_2)_nG]_m(CH_2)_p-$,

10 q is 0 or 1,

each D, E, and G independently are selected from $-O-$, $-NR^3-$, $-N(COR^4)-$, $-PR^5(O)-$, and $-P(OR^6)(O)-$, wherein R^3 , R^4 , R^5 , and R^6 independently represent hydrogen or C_{1-6} -alkyl,

Z is selected from $-C(O)NH-$, $-C(O)NHCH_2-$, $-OC(O)NH-$, $-C(O)NHCH_2CH_2-$,

15 $-C(O)CH_2-$, $-C(O)CH=CH-$, $-(CH_2)_s-$, $-C(O)-$, $-C(O)O-$ or $-NHC(O)-$, wherein s is 0 or 1,

Y is a chemical group linking B and the therapeutic agent, and

Y' is a chemical group linking B' and the therapeutic agent, and

W is a chemical group linking A and B, and

20 W' is a chemical group linking A' and B'.

5. A compound according to claim 4, wherein Y' is selected from the group consisting of $-C(O)NH-$, $-C(O)NHCH_2-$, $OC(O)NH-$, $-C(O)NHCH_2-$, $-C(O)CH_2-$, $-C(O)CH=CH-$, $-(CH_2)_s-$, $-C(O)-$, $-C(O)O-$ and $-NHC(O)-$, wherein s is 0 or 1.

25

6. A compound according to any one of claims 4-5, wherein W' is selected from the group consisting of $-C(O)NH-$, $-C(O)NHCH_2-$, $-OC(O)NH-$, $-C(O)CH_2-$, $-C(O)CH=CH-$, $-(CH_2)_s-$, $-C(O)-$, $-C(O)O-$ or $-NHC(O)-$, wherein s is 0 or 1.

30

7. A compound according to claim 2, which has the formula (III)



wherein

A and A' are albumin binding residues,

B is a hydrophilic spacer selected from $-(CH_2)_lD[(CH_2)_nE]_m(CH_2)_p-Q_q-$ wherein

l, m and n independently are 1-20 and p is 0-10,

Q is $-Z-(CH_2)_lD[(CH_2)_nG]_m(CH_2)_p-$,

q is 0 or 1,

each D, E, and G are independently selected from $-O-$, $-NR^3-$, $-N(COR^4)-$, $-PR^5(O)-$,
 5 and $-P(OR^6)(O)-$, wherein R^3 , R^4 , R^5 , and R^6 independently represent hydrogen or C_{1-8} -alkyl,

Z is selected from $-C(O)NH-$, $-C(O)NHCH_2-$, $-OC(O)NH-$, $-C(O)NHCH_2CH_2-$,
 $-C(O)CH_2-$, $-C(O)CH=CH-$, $-(CH_2)_s-$, $-C(O)-$, $-C(O)O-$ or $-NHC(O)-$, wherein s is 0 or
 1,

10 Y is a chemical group linking B and the therapeutic agent, and
 W'' is a chemical group linking B with A and A'.

8. A compound according to claim 7, wherein W'' is selected from the group consisting of
 $-C(O)NHCH-$, $-C(O)CH-$, $-(CH_2)_sCH-$, and $-NHC(O)CNHC(O)CH_2O(CH_2)_2O(CH_2)_2NH-$
 15 , wherein s is 0, 1 or 2.

9. A compound according to any one of claims 3-8, wherein Y is selected from the group
 consisting of $-C(O)NH-$, $-C(O)NHCH_2-$, $OC(O)NH-$, $-C(O)NHCH_2-$, $-C(O)CH_2-$,
 $-C(O)CH=CH-$, $-(CH_2)_s-$, $-C(O)-$, $-C(O)O-$ and $-NHC(O)-$, wherein s is 0 or 1.

20 10. A compound according to any one of claims 3-9, wherein W is selected from the group
 consisting of $-C(O)NH-$, $-C(O)NHCH_2-$, $-OC(O)NH-$, $-C(O)CH_2-$, $-C(O)CH=CH-$, $-(CH_2)_s-$,
 $-C(O)-$, $-C(O)O-$ or $-NHC(O)-$, wherein s is 0 or 1.

25 11. A compound according to any one of claims 2-10, wherein l is 1 or 2, n and m are inde-
 pendently 1-10 and p is 0-10.

12. A compound according to any one of claims 2-11, wherein D is $-O-$.

30 13. A compound according to any one of claims 2-12, wherein E is $-O-$.

14. A compound according to any one of claims 2-10, wherein the hydrophilic spacer is
 $-CH_2O[(CH_2)_2O]_m(CH_2)_pQ_q-$, where m is 1-10, p is 1-3, and Q is $-Z-CH_2O[(CH_2)_2O]_m(CH_2)_p-$.

35 15. A compound according to any of the previous claims, wherein q is 1.

16. A compound according to any one of claims 2-10 and 12-14, wherein G is -O-.
17. A compound according to any of the previous claims, wherein Z is selected from the group
5 consisting of -C(O)NH-, -C(O)NHCH₂-, and -OC(O)NH-.
18. A compound according to any one of claims 2-14, wherein q is 0.
19. A compound according to any one of claims 2-13, wherein l is 2.
- 10 20. A compound according to any of the previous claims, wherein n is 2.
21. A compound according to any one of claims 2-14, wherein the hydrophilic spacer B is -
[CH₂CH₂O]_{m+1}(CH₂)_pQ_q-.
- 15 22. A compound according to any of the previous claims, wherein the molar weight of said hydrophilic spacer is in the range from 80D to 1000D or in the range from 80D to 300D.
23. A compound according to any of the previous claims, wherein said albumin binding residue
20 is a lipophilic residue.
24. A compound according to any of the previous claims, wherein said albumin binding residue binds non-covalently to albumin.
- 25 25. A compound according to any of the previous claims, wherein said albumin binding residue is negatively charged at physiological pH.
26. A compound according to any of the previous claims, wherein said albumin binding residue has a binding affinity towards human serum albumin that is below about 10 μM or below about
30 1 μM.
27. A compound according to any of the previous claims, wherein said albumin binding residue is selected from a straight chain alkyl group, a branched alkyl group, a group which has an ω-carboxylic acid group, a partially or completely hydrogenated cyclopentanophenanthrene skeleton.
35 ton.

28. A compound according to any of the previous claims, wherein said albumin binding residue is a cibacronyl residue.

5 29. A compound according to any of the previous claims, wherein said albumin binding residue has from 6 to 40 carbon atoms, from 8 to 26 carbon atoms or from 8 to 20 carbon atoms.

30. A compound according to any of the previous claims, wherein said albumin binding residue is a peptide, such as a peptide comprising less than 40 amino acid residues.

10 31. A compound according to any one of the previous claims, wherein the albumin binding residue is attached to said therapeutic polypeptide via the ϵ -amino group of a lysine residue.

32. A compound according to any one of the previous claims, wherein the albumin binding residue is attached to said therapeutic polypeptide via an amino acid residue selected from cysteine, glutamate and aspartate.

33. A compound according to any of the previous claims, wherein said therapeutic polypeptide is a GLP-1 peptide.

20 34. A compound according to claim 33, wherein said polypeptide is a GLP-1 peptide comprising the amino acid sequence of the formula (IV):

Xaa₇-Xaa₈-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Xaa₁₆-Ser-Xaa₁₈-Xaa₁₉-Xaa₂₀-Glu-Xaa₂₂-Xaa₂₃-Ala-
Xaa₂₅-Xaa₂₆-Xaa₂₇-Phe-Ile-Xaa₃₀-Trp-Leu-Xaa₃₃-Xaa₃₄-Xaa₃₅-Xaa₃₆-Xaa₃₇-Xaa₃₈-Xaa₃₉-
25 Xaa₄₀-Xaa₄₁-Xaa₄₂-Xaa₄₃-Xaa₄₄-Xaa₄₅-Xaa₄₆

Formula (IV) (SEQ ID No: 2)

wherein

Xaa₇ is L-histidine, D-histidine, desamino-histidine, 2-amino-histidine, β -hydroxy-histidine, homohistidine, N^ε-acetyl-histidine, α -fluoromethyl-histidine, α -methyl-histidine, 3-pyridylalanine, 2-pyridylalanine or 4-pyridylalanine;

Xaa₈ is Ala, Gly, Val, Leu, Ile, Lys, Aib or (1-aminocycloalkyl) carboxylic acid;

Xaa₁₆ is Val or Leu;

Xaa₁₈ is Ser, Lys or Arg;

Xaa₁₉ is Tyr or Gln;

35 Xaa₂₀ is Leu or Met;

- Xaa₂₂ is Gly, Glu or Aib;
 Xaa₂₃ is Gln, Glu, Lys or Arg;
 Xaa₂₅ is Ala or Val;
 Xaa₂₆ is Lys, Glu or Arg;
 5 Xaa₂₇ is Glu or Leu;
 Xaa₃₀ is Ala, Glu or Arg;
 Xaa₃₃ is Val or Lys;
 Xaa₃₄ is Lys, Glu, Asn or Arg;
 Xaa₃₅ is Gly or Aib;
 10 Xaa₃₆ is Arg, Gly or Lys;
 Xaa₃₇ is Gly, Ala, Glu, Pro or Lys;
 Xaa₃₈ is Lys, Ser, NH₂ or is absent.
 Xaa₃₉ is Ser, Lys or is absent;
 Xaa₄₀ is Gly or is absent;
 15 Xaa₄₁ is Ala or is absent;
 Xaa₄₂ is Pro or is absent;
 Xaa₄₃ is Pro or is absent;
 Xaa₄₄ is Pro or is absent;
 Xaa₄₅ is Ser or is absent;
 20 Xaa₄₆ is NH₂ or is absent ;
 provided that if Xaa₃₈, Xaa₃₉, Xaa₄₀, Xaa₄₁, Xaa₄₂, Xaa₄₃, Xaa₄₄, Xaa₄₅ or Xaa₄₆ is absent then
 each amino acid residue downstream is also absent.

35. A compound according to claim 34, wherein said polypeptide is a GLP-1 peptide comprising the amino acid sequence of formula (V):

25 Xaa₇-Xaa₈-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Xaa₁₈-Tyr-Leu-Glu-Xaa₂₂-Xaa₂₃-Ala-Ala-
 Xaa₂₆-Glu-Phe-Ile-Xaa₃₀-Trp-Leu-Val-Xaa₃₄-Xaa₃₅-Xaa₃₆-Xaa₃₇-Xaa₃₈

Formula (V) (SEQ ID No: 3)

wherein

- 30 Xaa₇ is L-histidine, D-histidine, desamino-histidine, 2-amino-histidine, β -hydroxy-histidine, homohistidine, N^o-acetyl-histidine, α -fluoromethyl-histidine, α -methyl-histidine, 3-pyridylalanine, 2-pyridylalanine or 4-pyridylalanine;
 Xaa₈ is Ala, Gly, Val, Leu, Ile, Lys, Aib or (1-aminocycloalkyl) carboxylic acid;
 Xaa₁₈ is Ser, Lys or Arg;
 35 Xaa₂₂ is Gly, Glu or Aib;

Xaa₂₃ is Gln, Glu, Lys or Arg;

Xaa₂₈ is Lys, Glu or Arg;

Xaa₃₀ is Ala, Glu or Arg;

Xaa₃₄ is Lys, Glu or Arg;

5 Xaa₃₅ is Gly or Aib;

Xaa₃₈ is Arg or Lys;

Xaa₃₇ is Gly, Ala, Glu or Lys;

Xaa₃₈ is Lys, NH₂ or is absent.

10

36. A compound according to any one of claims 33-35, wherein said GLP-1 peptide is selected from GLP-1(7-35), GLP-1(7-36), GLP-1(7-36)-amide, GLP-1(7-37), GLP-1(7-38), GLP-1(7-39), GLP-1(7-40), GLP-1(7-41) or an analogue thereof.

15

37. A compound according to any one of claims 33-36, wherein said GLP-1 peptide comprises no more than fifteen amino acid residues which have been exchanged, added or deleted as compared to GLP-1(7-37) (SEQ ID No. 1), or no more than ten amino acid residues which have been exchanged, added or deleted as compared to GLP-1(7-37) (SEQ ID No. 1).

20

38. A compound according to claim 37, wherein said GLP-1 peptide comprises no more than six amino acid residues which have been exchanged, added or deleted as compared to GLP-1(7-37) (SEQ ID No. 1).

25

39. A compound according to any one of claims 37-38, wherein said GLP-1 peptide comprises no more than 4 amino acid residues which are not encoded by the genetic code.

40. A compound according to claim 33, wherein said GLP-1 peptide is a DPPIV protected GLP-1 peptide.

30

41. A compound according to any one of claims 33-40, wherein said GLP-1 peptide comprises an Aib residue in position 8.

35

42. A compound according to any one of claims 33-41, wherein the amino acid residue in position 7 of said GLP-1 peptide is selected from the group consisting of D-histidine, desamino-histidine, 2-amino-histidine, β -hydroxy-histidine, homohistidine, N ^{α} -acetyl-histidine, α -

fluoromethyl-histidine, α -methyl-histidine, 3-pyridylalanine, 2-pyridylalanine and 4-pyridylalanine.

43. A compound according to any one of claims 33-42, wherein said GLP-1 peptide is selected from the group consisting of Arg³⁴GLP-1(7-37), Arg³⁴GLP-1(7-37)-OH, Lys³⁸Arg^{26,34}GLP-1(7-38), Lys³⁸Arg^{26,34}GLP-1(7-38)-OH, Lys³⁸Arg^{26,34}GLP-1(7-36), Lys³⁸Arg^{26,34}GLP-1(7-36)-OH, Aib^{8,22,35}GLP-1(7-37), Aib^{8,35}GLP-1(7-37), Aib^{8,22}GLP-1(7-37), Aib^{8,22,35}GLP-1(7-37)-OH, Aib^{8,35}GLP-1(7-37)-OH, Aib^{8,22}GLP-1(7-37)-OH, Aib^{8,22,35}Arg^{26,34}Lys³⁸GLP-1(7-38)-OH, Aib^{8,35}Arg^{26,34}Lys³⁸GLP-1(7-38)-OH, Aib^{8,22}Arg^{26,34}Lys³⁸GLP-1(7-38)-OH, Aib^{8,22,35}Arg^{26,34}Lys³⁸GLP-1(7-38), Aib^{8,35}Arg^{26,34}Lys³⁸GLP-1(7-38), Aib^{8,22,35}Arg^{26,34}Lys³⁸GLP-1(7-38)-OH, Aib^{8,35}Arg^{26,34}Lys³⁸GLP-1(7-38)-OH, Aib^{8,22}Arg^{26,34}Lys³⁸GLP-1(7-38)-OH, Aib^{8,22,35}Arg²⁶Lys³⁸GLP-1(7-38), Aib^{8,35}Arg²⁶Lys³⁸GLP-1(7-38), Aib^{8,22,35}Arg²⁶Lys³⁸GLP-1(7-38)-OH, Aib^{8,35}Arg²⁶Lys³⁸GLP-1(7-38)-OH, Aib^{8,22}Arg²⁶Lys³⁸GLP-1(7-38)-OH, Aib^{8,22,35}Arg³⁴Lys³⁸GLP-1(7-38), Aib^{8,35}Arg³⁴Lys³⁸GLP-1(7-38), Aib^{8,22}Arg³⁴Lys³⁸GLP-1(7-38), Aib^{8,22,35}Arg³⁴Lys³⁸GLP-1(7-38)-OH, Aib^{8,35}Arg³⁴Lys³⁸GLP-1(7-38)-OH, Aib^{8,22}Arg³⁴Lys³⁸GLP-1(7-38)-OH, Aib^{8,22,35}Ala³⁷Lys³⁸GLP-1(7-38), Aib^{8,35}Ala³⁷Lys³⁸GLP-1(7-38), Aib^{8,22}Ala³⁷Lys³⁸GLP-1(7-38), Aib^{8,22,35}Ala³⁷Lys³⁸GLP-1(7-38)-OH, Aib^{8,35}Ala³⁷Lys³⁸GLP-1(7-38)-OH, Aib^{8,22}Ala³⁷Lys³⁸GLP-1(7-38)-OH, Aib^{8,22,35}Lys³⁷GLP-1(7-37), Aib^{8,35}Lys³⁷GLP-1(7-37), Aib^{8,22}Lys³⁷GLP-1(7-38), Aib^{8,22,35}Lys³⁷GLP-1(7-37)-OH, Aib^{8,35}Lys³⁷GLP-1(7-37)-OH, and Aib^{8,22}Lys³⁷GLP-1(7-38)-OH,
44. A compound according to any one of claims 33-43, wherein said GLP-1 peptide is attached to said hydrophilic spacer via the amino acid residue in position 23, 26, 34, 36 or 38 relative to the amino acid sequence SEQ ID No:1.
45. A compound according to any one of claims 33-36, wherein said GLP-1 peptide is extendin-
- 4.
46. A compound according to any one of claims 33-36, wherein said GLP-1 peptide is ZP-10, i.e. HGEFTFTSDLSKQMEEEAVRLFIEWLKNGGPSSGAPPSKKKKKK-NH₂.


47. A compound according to any one of claims 33-46, wherein one albumin binding residue via said hydrophilic spacer is attached to the C-terminal amino acid residue of said GLP-1 peptide.

5 48. A compound according to claim 47, wherein a second albumin binding residue is attached to an amino acid residue which is not the C-terminal amino acid residue.

49. A compound according to any one of claims X-Y (?), wherein said compound is selected from the group consisting of


- 10 N^{ε37}-(2-(2-(2-(dodecylamino)ethoxy)ethoxy)acetyl)-[Aib^{8,22,35}] GLP-1 H-(7-37)-NH₂,
N^{ε37}-(2-(2-(2-(17-sulphohexadecanoylamino)ethoxy)ethoxy)acetyl)-[Aib^{8,22,35},Lys³⁷] GLP-1
H-(7-37)-NH₂,
N^{ε37}-(2-[2-(2-(15-carboxyhexadecanoylamino)ethoxy)ethoxy]acetyl)-[Aib^{8,22,35},Lys³⁷] GLP-1
H-(7-37)-NH₂,
15 N^{ε37}-(2-(2-(2-(17-carboxyheptadecanoylamino)ethoxy)ethoxy)acetyl)-[Aib^{8,22,35},Lys³⁷] GLP-1 H
(7-37)-NH₂,
N^{ε37}-(2-(2-(2-(19-carboxynonadecanoylamino)ethoxy)ethoxy)acetyl)-[Aib^{8,22,35},Lys³⁷] GLP-1 H
(7-37)-NH₂,
N^{ε38}-(4-(hexadecanoylamino)-4(S)-carboxybutyryl)-[Aib^{8,22,35},Arg^{26,34}] GLP-1 H-(7-37) Lys
20 NH₂,
N^{ε38}-(2-(2-(2-(hexadecanoylamino)ethoxy)ethoxy)acetyl)-[Aib^{8,22,35},Arg^{26,34}] GLP-1 H-(7-
37)Lys NH₂,
N^{ε37}(2-[2-(2,6-(S)-Bis-{2-[2-(2-
(dodecanoylamino)ethoxy)ethoxy]acetylaminohexanoylamino)ethoxy]ethoxy))
25 acetyl-[Aib^{8,22,35}]GLP-1 H-(7-37)-NH₂,
N^{ε37}-(2-[2-(2,6-(S)-Bis-{2-[2-(2-
(tetradecanoylamino)ethoxy)ethoxy]acetylaminohexanoylamino)ethoxy]ethoxy))
acetyl-[Aib^{8,22,35}]GLP-1 H-(7-37)-NH₂,
N^{ε38}-epsilon38-(2-(2-(2-(4-(hexadecanoylamino)-4(S)-
30 carboxybutyrylamino)ethoxy)ethoxy)acetyl)-[Aib^{8,22,35},Arg^{26,34}] GLP-1 H-(7-37) Lys-OH,
N^{ε38}-(2-[2-[4-[4-(4-Amino-9,10-dioxo-3-sulfo-9,10-dihydro-anthracen-1-ylamino)-2-sulfo-
phenylamino]-6-(2-sulfo-phenylamino)-[1,3,5]triazin-2-ylamino]-ethoxy]-ethoxy)-acetyl)-
[Aib^{8,22,35}] GLP-1 H (7-37)Lys-NH₂,


- $N^{\epsilon 38}$ -((2-[2-(2-[2-(2-[2-(2-[2-(15-carboxypentadecanoylamino)-ethoxy]ethoxy)acetyl]amino)ethoxy]ethoxy)acetyl]amino)ethoxy]ethoxy)acetyl)- [Aib^{8,22,35}]
 GLP-1 H (7-37)Lys- NH₂,
 $N^{\epsilon 38}$ -[[2-(2-[3-[2,5-dioxo-3-(15-carboxypentadecylsulfanyl)-pyrrolidin-1-yl]-propionylamino]ethoxy)ethoxy]acetyl]-[D-Ala⁸,Lys³⁷]-GLP-1-[7-37]NH₂,
 5 $N^{\epsilon 38}$ -(2-(2-(2-(11-(oxalylamino)undecanoylamino)ethoxy)ethoxy)acetyl)-) [Aib^{8,22,35}, Ala³⁷,Lys³⁸] GLP-1 H-(7-37)Lys-NH₂,
 $N^{\epsilon 38}$ -(2-[2-(2-[2-(2-(15-carboxy-pentadecanoylamino)-ethoxy]ethoxy)acetyl]amino)ethoxy]ethoxy)acetyl)[Aib^{8,22,35},Ala³⁷]-GLP-1[7-37]Lys NH₂,
 10 $N^{\epsilon 38}$ -((2-[2-[11-(5-Dimethylaminonaphthalene-1-sulfonylamino)undecanoylamino]ethoxy]ethoxy)acetyl [Aib^{8,22,35},Ala³⁷]-GLP-1[7-37]LysNH₂,
 $N^{\epsilon 38}$ [[2-(2-[2-[1-(4-Chlorobenzoyl)-5-methoxy-2-methyl-1H-indol-3-yl]acetyl]amino)ethoxy]ethoxy]acetyl) [Aib^{8,22,35},Ala³⁷]-GLP-1(7-37)Lys-NH₂,
 $N^{\epsilon 38}$ -2-(2-(2-(octadecanoylamino)ethoxy)ethoxy)acetyl [Aib⁸,Arg^{26,34},Glu^{22,23,30}]GLP-1 H(7-
 15 37)Lys-NH₂,
 $N^{\epsilon 38}$ -2-(2-(2-(eicosanoylamino)ethoxy)ethoxy)acetyl [Aib⁸,Arg^{26,34},Glu^{22,23,30}]GLP-1 H(7-37)Lys-NH₂,
 Gly⁸,Arg^{26,34,36},Lys³⁸ (N-epsilon((2-[2-(2-[2-(2-[4-Carboxy-4-octadecanoylamino-butyrylamino)ethoxy]ethoxy)acetyl]amino)ethoxy]ethoxy)-acetic acid))GLP-1 (7-38),



20

Aib⁸,Lys³⁸-(N-epsilon-2-(2-(2-(gamma-glutamyl(N-alfa-hexadecanoyl))aminoethoxy)ethoxy)acetyl)-GLP-1 (7-38),





Aib8,Lys38-(N-epsilon-2-(2-(2-(2-(2-(gamma-glutamyl(N-alfa-hexadecanoyl))aminoethoxy)ethoxy)acetyl)

5 aminoethoxy)ethoxy)acetyl-GLP-1 (7-38),

[Aib8,22,35,Lys(C12oyl-Aminoethoxy-ethoxyAcetyl-)37] GLP-1 H-(7-37)-NH2,

Aib8,22,35,Lys(N-epsilon-C14oyl-aminoethoxyethoxyacetyl-)37] GLP-1 -(7-37)-NH2,

[Aib8,22,35,Lys(C16oyl-Aminoethoxy-ethoxyAcetyl-)37] GLP-1 H-(7-37)-NH2,

[Aib8,22,35,Lys(C18oyl-Aminoethoxy-ethoxyAcetyl-)37] GLP-1 H-(7-37)-NH2 and

10 [Aib8,22,35,Lys(C20oyl-Aminoethoxy-ethoxyAcetyl-)37] GLP-1 H-(7-37)-NH2.

50. A compound according to any one of claims 1-32, wherein said therapeutic polypeptide is a GLP-2 peptide.

15 51. A compound according to claim 50, wherein said GLP-2 peptide is a DPPIV-protected GLP-2 peptide.

52. A compound according to claim 50, wherein said GLP-2 peptide is Gly²-GLP-2(1-33).

20 53. A compound according to claim 50, wherein said GLP-2 peptide is Lys¹⁷Arg³⁰-GLP-2(1-33).

54. A compound according to any one of claims 1-32, wherein said therapeutic polypeptide is human insulin or an analogue thereof.

25 55. A compound according to claim 54, wherein said therapeutic polypeptide is selected from the group consisting of Asp^{B28}-human insulin, Lys^{B28},Pro^{B29}-human insulin, Lys^{B3},Glu^{B29}-human insulin, Gly^{A21},Arg^{B31},Arg^{B32}-human insulin and des(B30) human insulin.

56. A compound according to any one of claims 1-32, wherein said therapeutic polypeptide is human growth hormone or an analogue thereof.
57. A compound according to any one of claims 1-32, wherein said therapeutic polypeptide is parathyroid hormone or an analogue thereof.
58. A compound according to any one of claims 1-32, wherein said therapeutic polypeptide is human follicle stimulating hormone or an analogue thereof.
59. A compound according to any one of claims 1-32, wherein said therapeutic polypeptide has a molar weight of less than 100 kDa, less than 50 kDa, or less than 10 kDa.
60. A compound according to any one of claims 1-32, wherein said therapeutic polypeptide is selected from the group consisting of a growth factor such as platelet-derived growth factor (PDGF), transforming growth factor α (TGF- α), transforming growth factor β (TGF- β), epidermal growth factor (EGF), vascular endothelial growth factor (VEGF), a somatomedin such as insulin growth factor I (IGF-I), insulin growth factor II (IGF-II), erythropoietin (EPO), thrombopoietin (TPO) or angiopoietin, interferon, pro-urokinase, urokinase, tissue plasminogen activator (t-PA), plasminogen activator inhibitor 1, plasminogen activator inhibitor 2, von Willebrandt factor, a cytokine, e.g. an interleukin such as interleukin (IL) 1, IL-1Ra, IL-2, IL-4, IL-5, IL-6, IL-9, IL-11, IL-12, IL-13, IL-15, IL-16, IL-17, IL-18, IL-20 or IL-21, a colony stimulating factor (CSF) such as GM-CSF, stem cell factor, a tumor necrosis factor such as TNF- α , lymphotoxin- α , lymphotoxin- β , CD40L, or CD30L, a protease inhibitor e.g. aprotinin, an enzyme such as superoxide dismutase, asparaginase, arginase, arginine deaminase, adenosine deaminase, ribonuclease, catalase, uricase, bilirubin oxidase, trypsin, papain, alkaline phosphatase, β -glucuronidase, purine nucleoside phosphorylase or batroxobin, an opioid, e.g. endorphins, enkephalins or non-natural opioids, a hormone or neuropeptide, e.g. calcitonin, glucagon, gastrins, adrenocorticotrophic hormone (ACTH), cholecystokinins, lutenizing hormone, gonadotropin-releasing hormone, chorionic gonadotropin, corticotrophin-releasing factor, vasopressin, oxytocin, antidiuretic hormones, thyroid-stimulating hormone, thyrotropin-releasing hormone, relaxin, prolactin, peptide YY, neuropeptide Y, pancreatic polypeptide, leptin, CART (cocaine and amphetamine regulated transcript), a CART related peptide, perilipin, melanocortins (melanocyte-stimulating hormones) such as MC-4, melanin-concentrating hormones, natriuretic peptides, adrenomedullin, endothelin, secretin, amylin, vasoactive intestinal peptide (VIP), pituitary adenylate cyclase activating polypeptide (PACAP), bombesin,

bombesin-like peptides, thymosin, heparin-binding protein, soluble CD4, hypothalamic releasing factor, melanotonins and analogues thereof.

61. A pharmaceutical composition comprising a compound according to any one of claims 1-60, and a pharmaceutically acceptable excipient.

62. The pharmaceutical composition according to claim 61, which is suited for parenteral administration.

63. Use of a compound according to any one of the claims 1-60 for the preparation of a medicament.

64. Use of a compound according to any one of the claims 33-49 for the preparation of a medicament for the treatment or prevention of hyperglycemia, type 2 diabetes, impaired glucose tolerance, type 1 diabetes, obesity, hypertension, syndrome X, dyslipidemia, β -cell apoptosis, β -cell deficiency, myocardial infarction, inflammatory bowel syndrome, dyspepsia, cognitive disorders, e.g. cognitive enhancing, neuroprotection, atherosclerosis, coronary heart disease and other cardiovascular disorders.

65. Use of a compound according to any one of claims 50-53 for the preparation of a medicament for the treatment of small bowel syndrome, inflammatory bowel syndrome or Crohns disease.

66. Use of a compound according to any one of claims 54-55 for the preparation of a medicament for the treatment or prevention of hyperglycemia, type 1 diabetes, type 2 diabetes or β -cell deficiency.

ABSTRACT

Novel polypeptide derivatives having protracted profile of action.